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Abstract 
Background and Aims 
Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation 
of the metabolic syndrome and is strongly linked with obesity and type 2 
diabetes. The role of gut-liver interaction is increasingly recognised in the 
development of NAFLD. Modification of gut microbiota may lower 
cardiovascular risk and reduce liver injury beyond existing treatment in those 
with NAFLD. This study tests the hypothesis that probiotic supplementation 
may improve endothelial function and insulin sensitivity; and reduce oxidative 
stress, inflammation and liver injury in subjects with NAFLD.  
 
Methods 
This is a randomised, double-blinded, placebo-controlled, proof-of-concept trial 
in which subjects with NAFLD are allocated to take either two sachets VSL#3 
probiotic twice daily or the placebo equivalent for 10 weeks. Biophysical 
markers for endothelial function, oxidative stress, vascular inflammation, insulin 
resistance and liver injury were undertaken before and after the intervention 
period. 
 
Results 
Forty-two patients participated and 35 of them completed the study. There 
were 28 males and 7 females; and 74% had type 2 diabetes or impaired fasting 
glycaemia. Mean age was 57 ± 8 years, body mass index 32.6 ± 5.0 kg/m2, blood 
pressure 134/82 ± 13/7 mmHg, HbA1c 53 ± 14 mmol/mol (7.0 ± 3.4%), total 
cholesterol 4.42 ± 1.15mmol/l, HDL 1.06 ± 0.29mmol/l, LDL 2.43 ± 1.06 mmol/l, 
triglycerides 2.00 ± 0.88 mmol/l, ALT 53 ± 26 iu/l and AST 40 ± 15 iu/l. Median 
duration of NAFLD was 0.3 ± IQR 2.0 years. No significant difference was seen in 
markers of cardiovascular risk and liver injury following VSL#3 probiotic 
supplementation.  
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Conclusion 
There was no significant improvement in the markers of endothelial function, 
oxidative stress, inflammation, insulin resistance, liver fibrosis scores, liver 
transaminases or liver imaging in this group of patients with NAFLD treated with 
10 weeks of VSL#3 probiotic supplementation. The results may be due to a 
number of factors such as a small sample size, subjects with relatively good 
metabolic control and possibly less severe liver disease, and the lack of 
consensus on an effective dose and duration of probiotic supplementation. 
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Introduction 
Non-alcoholic fatty liver disease 
Definition 
NAFLD refers to the accumulation of fat in the liver exceeding 5% of liver weight 
in the absence of excessive alcohol consumption and other underlying 
secondary causes of chronic liver disease. It is one of the most common causes 
of abnormal liver enzymes and chronic liver disease in the Western world. 
Clinically it covers a spectrum of liver pathology including steatosis, non-
alcoholic steatohepatitis (NASH), fibrosis and cirrhosis.  
 
Epidemiology and Natural history 
The prevalence of NAFLD is estimated to be 20-30% in the Western countries 
(1) and 6-35% worldwide (2). The true incidence of this condition is unknown 
due to lack of large prospective studies. NAFLD is strongly associated with 
obesity (3) and type 2 diabetes mellitus (T2DM) (4). NAFLD is regarded as the 
hepatic manifestation of the metabolic syndrome, a constellation of clinical 
features underpinned by insulin resistance (5). The definition of the metabolic 
syndrome is illustrated in Table 1.1 (6). 
 
Table 1.1: IDF definition of the metabolic syndrome 
Central obesity (defined as waist circumference which is ethnic-specific) 
 European waist circumference: ≥ 94cm for males, ≥ 80cm for females 
 BMI > 30kg/m2 assumed to have central obesity 
 
Plus any 2 of the following 4 factors: 
Raised triglycerides ≥ 1.7mmol/l 
or specific treatment for this lipid abnormality 
Reduced HDL cholesterol < 1.03mmol/l in males 
< 1.29mmol/l in females 
or specific treatment for this lipid abnormality 
Raised blood pressure 
(BP) 
Systolic BP ≥ 130mmHg  
Diastolic BP ≥ 85mmHg 
or previously diagnosed hypertension 
Raised fasting plasma 
glucose (FPG) 
FPG ≥ 5.6mmol/l 
or previously diagnosed type 2 diabetes 
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The natural history of NAFLD has been well described in the literature. De Alwis 
and Day summarised that 12-40% patients with simple steatosis progress to 
NASH with early fibrosis after 8-13 years; 5-10% patients with NASH and early 
fibrosis will progress to more advanced liver disease; and up to 50% of those 
with advanced fibrosis will develop cirrhosis. Approximately 7% of patients with 
cirrhosis will develop hepatocellular carcinoma within 10 years, and 50% will 
need a liver transplant or die from a liver-related cause (7). 
 
Data from the NASH Clinical Research Network suggested that patients with 
NASH are more likely to be female, have diabetes and insulin resistance, and 
higher liver transaminases (8). A Swedish study of patients with biopsy proven 
NAFLD over a mean of 13.7 years found that the risk of fibrosis progression is 
associated with insulin resistance, weight gain, higher transaminases, lower 
platelet count and more pronounced hepatic fatty infiltration (9). 
Survival was lower in the patients with NAFLD compared to sex and age-
matched population, and the leading causes of death were ischaemic heart 
disease, malignancy and liver disease (10,11). Hepatic steatosis per se appears 
to have a more clinically benign course whereas NASH is associated with more 
progressive liver disease and increased mortality (9,11,12).  
 
Clinical features and diagnosis  
Many individuals with NAFLD are asymptomatic although reported symptoms 
include fatigue and right upper quadrant discomfort (13). Often individuals are 
referred to secondary care with incidental finding of raised liver transaminase(s) 
or hepatomegaly, or may present acutely with sequelae of liver cirrhosis. 
Features of the metabolic syndrome are commonly associated with underlying 
NAFLD and a high index of suspicion is necessary to diagnose NAFLD early.  
 
The diagnosis of NAFLD is based on histological or radiological evidence of 
hepatic fat accumulation in the absence of excessive alcohol intake and 
secondary causes of chronic liver disease (viral hepatitis, haemochromatosis, 
Wilson’s disease, alpha-1 antitrypsin deficiency and hepatotoxic drugs) (14). 
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Whilst raised serum transaminases suggest the presence of liver disease, they 
are not a sensitive tool for diagnosing NAFLD as a proportion of patients, 
irrespective of histological severity , have normal liver enzymes (13). 
Ultrasound, CT and MRI can detect steatosis when fatty infiltration exceeds a 
third of the liver. However, none of these imaging modalities can accurately 
distinguish NASH or fibrosis from pure steatosis (15). As previously mentioned, 
it is important to make such distinction clinically as NASH and more severe 
forms of NAFLD confer greater morbidity and mortality.  
 
A liver biopsy is the gold standard test to diagnose and stage the severity of 
NAFLD.  This procedure is invasive and associated with potentially serious 
complications (16). Other limitations of liver biopsy include the risk of sampling 
error (17), and inter- and intra-observer variation in histological interpretation. 
Furthermore, using liver biopsy to screen a condition that affects approximately 
a third of the population is neither practical nor financially plausible. 
Consequently, considerable attention has been directed towards the 
development of non-invasive markers/tools as a means of predicting advanced 
fibrosis. 
 
Several scoring systems (e.g. NAFLD fibrosis risk score, FIB-4, ELF and BARD) 
using a number of variables including serum biochemical markers of liver injury 
may be used in clinical practice to predict the presence of advanced fibrosis in 
patients with NAFLD (18–21).  Details of several predictive models of advanced 
fibrosis are shown in Table 1.2. Transient elastography (FibroScan) measures 
liver stiffness and distinguishes NASH and fibrosis with good accuracy, 
significantly better than biomarkers such as AST/ALT ratio and BARD fibrosis 
score (22).  
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Table 1.2: Predictive models of advanced fibrosis (F3-F4) in NAFLD 
Predictive model Variables used Threshold for 
presence of F3-4 
NAFLD fibrosis 
risk score (18) 
Age, BMI, presence of 
hyperglycaemia, platelet count, 
serum albumin and AST/ALT 
ratio 
> 0.675 
FIB4 index (19) Age, platelet count, AST and ALT > 2.67 
ELF panel (20) Tissue inhibitor of matrix 
metalloproteinase -1, hyaluronic 
acid and aminoterminal peptide 
of pro-collagen III 
≥ 0.3576 
BARD score (21) BMI, AST/ALT ratio and 
presence of diabetes 
≥ 2 
ELF – Enhanced Liver Fibrosis; BARD – BMI, AST/ALT ratio and Diabetes  
 
However, none of these non-invasive tools can accurately stage the degree of 
liver injury and as yet, cannot replace liver biopsy. In practice, many clinicians 
may use such tools to identify patients with possible advanced fibrosis and offer 
them a liver biopsy instead of performing a routine biopsy in all patients with 
NAFLD. As simple steatosis appears to have a more favourable outcome, one 
could argue that a liver biopsy is unlikely to change clinical management which 
is to offer lifestyle advice and screening for features of the metabolic syndrome. 
At present there is no proven cure for NAFLD and treatment is aimed at 
improving cardiometabolic risk profile. In a recent systematic review of 
treatments in NAFLD, weight loss (≥ 7%) and pioglitazone improved liver 
histology (steatosis and inflammation) and cardiometabolic risk profile (23). 
 
Pathophysiology 
The pathogenesis of NAFLD and its progression to more advanced liver disease 
is complex and not fully understood. A ‘two hit theory’ was previously described 
whereby the ‘first hit’ involves hepatic accumulation of triglycerides increasing 
hepatocyte susceptibility to injury. The ‘second hit’ is caused by the generation 
of reactive oxygen species (ROS) with subsequent lipid peroxidation and release 
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of proinflammatory cytokines resulting in liver injury, inflammation and fibrosis 
(24). However, it is increasingly recognised that other mechanisms such as free 
fatty acid (FFA) mediated inflammation, endoplasmic reticulum (ER) stress and 
gut-derived endotoxinaemia contribute to the development and progression of 
NAFLD (25,26).  
 
Hepatic steatosis 
Hepatic accumulation of triglycerides (TAG) is a consequence of increased FFA 
in the liver from three main sources (27):  
i. Lipolysis in adipose tissue  
ii. De novo lipogenesis  
iii. A fat-rich diet  
 
Expanded adipose tissue is a metabolically active organ that promotes low-
grade inflammation (28). In mouse models, macrophage infiltration into 
expanding adipocytes was associated inflammation and release of pro-
inflammatory cytokines which in turn impair insulin signalling pathways 
resulting in insulin resistance (29). In an insulin resistant state, there is 
inadequate suppression of hormone-sensitive lipase (HSL) causing increased 
free fatty acid (FFA) formation and delivery to the liver. In the liver, FFAs 
undergo β-oxidation or esterification with glycerol to form TAG. TAG are either 
stored in hepatocytes causing fat accumulation in the liver or exported as very 
low density lipoprotein (VLDL). Hyperinsulinaemia and hyperglycaemia 
upregulate the transcriptional activity of sterol-regulatory-element binding 
protein 1c (SREBP1c) and carbohydrate response element-binding protein 
(ChREBP) stimulating lipogenic genes involved in de novo lipogenesis (30). These 
mechanisms coupled with increased influx of intrahepatic FFAs from a fat rich 
diet lead to the development of hepatic steatosis.  
 
Inflammation and insulin resistance 
Hepatic steatosis is associated with a chronic inflammatory state within the liver 
as a result of the activation of I-κB kinase β (IKKß)/nuclear factor kappa β (NF-
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κB) pathway and subsequent production of proinflammatory cytokines such as 
TNFα, IL-6 and IL-1β shown in animal studies (31). FFAs can also directly activate 
the IKKß/NF-κB pathway via lysosomal destabilisation and release of cathepsin-
B which leads to production of TNFα (32). Hepatic inflammation causes hepatic 
and systemic insulin resistance via the activation of IKKß/NF-κB, c-Jun N-
terminal kinase (JNK) and protein kinase C (PKCε) pathways, and overexpression 
of suppressors of cytokine signalling (SOCS) (31,33,34). 
 
Oxidative stress 
FFAs are ligands for peroxisome proliferator activated receptor alpha (PPARα), a 
transcription factor involved in regulating genes responsible for peroxisomal, 
mitochondria and microsomal fat oxidation in the liver. With increased hepatic 
FFAs, upregulation of these genes leads to increased fat oxidation (26). Reactive 
oxygen species (ROS) are generated as a consequence of augmented β-
oxidation causing oxidative stress with subsequent activation of inflammatory 
pathways, lipid peroxidation and mitochondrial dysfunction (26,35). Oxidative 
stress associated with CYP2EI induction (cytochrome P450 isoform) was 
demonstrated in patients with steatosis and exacerbated in NASH (36). 
 
Endoplasmic reticulum stress 
Endoplasmic reticulum (ER) stress occurs when metabolic demands, from 
increased protein load in the ER, exceed the ER capacity to process these 
proteins. This imbalance can be caused by a variety of biological stresses such 
as hyperinsulinaemia and lipotoxicity, which result in activation of transcription 
factors and kinases. Hepatic ER stress has been implicated in the development 
of NAFLD (37). In animal studies, hepatic ER stress is associated with insulin 
resistance and hepatic steatosis via JNK (38), and SREBP-1c activation 
respectively (39). 
 
Gut-liver interaction 
Gut microbiota and gut-derived endotoxinaemia have received much interest in 
the development of NAFLD. This was comprehensively reviewed by Abu-Shanab 
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and Quigley (40). Normally the upper small intestine is populated by only small 
numbers of gram positive bacteria whereas coliforms and anaerobes inhabit the 
distal jejunum and colon in larger concentrations. SIBO is defined as the 
presence of excessive bacteria in the small intestine (41). Notably, there is a 
higher prevalence of small intestinal bacteria overgrowth (SIBO) in patients with 
NAFLD (42–44).  
 
In the context of SIBO, gram negative bacteria in the small intestine produce 
endotoxins and their active component, lipopolysaccharide (LPS), exerts 
metabolic and inflammatory effects on the liver. Alterations in gut microbiota 
can be influenced by diet with a high fat diet enhancing the proportion of LPS-
producing bacteria in the gut and a 2-3 fold increase in LPS concentration (45). 
LPS disrupt tight junctions between intestinal epithelial cells, compromising 
intestinal barrier integrity and increasing gut permeability therefore allowing 
translocation of endotoxins into the portal circulation where they are 
transported to the liver (40,42).  
 
Within the liver, LPS activates the TLR4 (Toll-like receptor 4)-dependent 
pathway in Kupffer cells resulting in activation of IKKB/NF- κB and JNK pathways 
which in turn triggers the release of proinflammatory cytokines (such as TNFα 
and IL-8), and impairs insulin signalling pathways therefore contributing to 
insulin resistance. This is supported by increased expression of TLR4 on CD14-
positive cells and higher IL-8 levels in patients with NASH (44), and increased 
expression of cytokines and phosphorylated forms of IKKB/NF- κB in obese mice 
infused with LPS (45).  In addition, LPS promotes the production of ROS and may 
be involved with hepatic fibrogenesis (40,46). 
 
Separately, intestinal bacteria also produce potentially hepatotoxic by-products 
such as ethanol and ammonia. Ethanol contributes to intestinal barrier 
impairment, and promotes inflammation and production of ROS similar to LPS 
(40,46).  
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Adipokines 
Adipocyte-derived cytokines may be involved in the pathogenesis of NAFLD. 
Hypoadiponectinaemia is associated with NAFLD, particularly a more severe 
form of the disease (47,48). Adiponectin increased insulin sensitivity, reduced 
hepatic fat accumulation and reduced TNFα in animal studies of NAFLD and 
AFLD, suggesting protective properties against fatty liver disease (49).  
Conversely, leptin levels are raised in NAFLD (50,51). Leptin enhances 
inflammation in an already injured liver with evidence of augmented TNFα 
expression and worsening necroinflammatory changes. However, its exact role 
in modulating proinflammatory responses is not fully understood (52).  
 
Hepatic fibrosis 
Hepatic fibrosis is characterised by activation of hepatic stellate cells (HSC) 
resulting in the production and deposition of extracellular matrix proteins. This 
process is secondary to chronic inflammation and hepatocyte injury, and is 
considered a ‘healing’ response (26). Leptin, angiotensin II and norepinephrine 
were shown to activate HSCs whilst reduced adiponectin contributes to liver 
fibrosis (52–56). LPS may activate HSCs through the TLR4-dependent pathway 
as TLR4 are also expressed in HSCs (57). Hyperglycaemia and hyperinsulinaemia 
have a direct fibrogenic role through expression of connective tissue growth 
factor in HSCs (58). Protracted fibrosis results in the development of cirrhosis. 
 
Taken together, the above mechanisms act in concert resulting in hepatocyte 
injury. Insulin resistance plays a central role in perpetuating these processes 
resulting in a vicious cycle of hepatocyte inflammation, injury and cell death. 
Over time simple steatosis may develop into NASH, fibrosis and ultimately 
cirrhosis.  
 
NAFLD and cardiovascular risk 
Existing evidence that suggest patients with NAFLD are at a higher risk of 
developing cardiovascular disease (CVD), independent of insulin resistance, 
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metabolic syndrome, and conventional cardiovascular risk factors such as 
hypertension and hyperlipidaemia are discussed below. 
 
Subclinical cardiovascular disease 
Carotid intima media thickness (CIMT) is a subclinical marker of atherosclerosis 
which predicts future cardiovascular events (59). A number of studies including 
a systematic review have demonstrated increased CIMT and higher prevalence 
of carotid plaques in patients with NAFLD (60–64). It is noteworthy that the 
severity of liver disease correlated positively with CIMT (62). Although it is not 
possible to determine the severity of liver disease based on serum 
transaminases, raised alanine aminotransferase (ALT) was associated with 
higher risk of developing carotid atherosclerosis in patients with NAFLD (65).  
 
The RISC study examined the relation between insulin resistance and 
cardiovascular risk in a clinically healthy European Caucasian population. The 
presence of NAFLD was predicted using the fatty liver index (FLI). Those with FLI 
>60 (i.e. 78% likelihood of NAFLD) had more insulin resistance, higher 10-year 
coronary heart disease score and increased carotid IMT (64). Other studies have 
also reported a higher 10 year cardiovascular risk in those with NAFLD (66). 
 
Endothelial dysfunction is marker of early atherosclerosis and plays an 
important role in the pathogenesis of atherosclerosis (67). Villanova et al. used 
ultrasound guided assessment of flow-mediated brachial artery vasodilatation 
(FMV) in response to ischaemia, a measure of endothelial function, in patients 
with NAFLD. Percentage FMV, following ischaemia, was significantly reduced in 
those with NAFLD and inversely correlated with the severity of liver disease 
(66). Using serum transaminases as a surrogate marker of NAFLD, elevated ALT 
was negatively associated with FMV (68). Endothelial dysfunction in patients 
with NAFLD was also reported using strain-gauge plethysmography (69), and 
the PulsePen device measuring pulse wave velocity (70). 
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Plasma biomarkers of inflammation and endothelial dysfunction (highly-
sensitive CRP, fibrinogen, von Willebrand factor and plasminogen activator 
inhibitor-1 activity) were significantly raised in apparently healthy men with 
NAFLD (71). Highly-sensitive CRP (hsCRP) is a novel biomarker of cardiovascular 
risk (72) which has been shown to be elevated in patients with NAFLD 
independent of other features of the metabolic syndrome (73,74). 
 
Coronary artery calcification is an indicator of subclinical coronary artery 
disease which can be measured using the coronary artery calcium score (CACS). 
This score is strongly associated with risk of coronary events (75,76). Studies 
have demonstrated a significant association between NAFLD and CACS (77,78). 
 
As previously discussed, hypoadiponectinaemia has been reported in NAFLD 
(47,48). In patients with type 2 diabetes, hypoadiponectinaemia was associated 
with increased CIMT (79). Adiponectin inhibits monocyte adhesion on the 
endothelium, expression of various adhesion molecules (e.g. VCAM-1) and 
growth factors (e.g. platelet-derived growth factor), and the proliferation and 
migration of smooth muscle cells (80). This supports an atherogenic role of 
hypoadiponectinaemia in NAFLD. 
 
Clinical cardiovascular disease 
A number of studies have reported increased risk of cardiovascular events and 
mortality in individuals with NAFLD independent of conventional risk factors 
and the metabolic syndrome (4,9,11,73,81–84). Details of these studies are 
summarised in Table 1.3 and Table 1.4 for cardiovascular events and mortality 
respectively. It should be noted that these data are mainly derived from 
population-based studies and therefore, have associated limitations such as 
heterogeneity in the diagnosis of NAFLD and outcome measures, presence of 
confounding factors, and difficulty establishing causality of relationships 
between NAFLD and cardiovascular outcomes. 
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The exact mechanisms in which NAFLD leads to a phenotype with higher 
cardiovascular risk are not completely understood. Figure 1.1 illustrates 
biological mechanisms involved in the development of NAFLD and how these 
potentially contribute to accelerated atherosclerosis. Importantly, NAFLD and 
atherosclerosis are chronic inflammatory conditions that seem to share 
common pathways (endothelial dysfunction, oxidative stress and 
inflammation). It is not known whether the liver is the primary site that drives 
atherosclerotic processes or whether the liver is one of the target organs of 
obesity-related systemic insulin resistance and inflammation which drives 
atherosclerosis. The close relationship between NAFLD and insulin resistance 
makes it challenging to distinguish the cause-effect relationship leading to 
increased cardiovascular risk. Nonetheless, given the current evidence, it is 
important to identify patients with NAFLD to assess their overall 
cardiometabolic status and address risk factors appropriately.  
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Table 1.3: Studies on cardiovascular events in patients with NAFLD (4,73,81–83) 
Authors Study details Results 
Targher et al. 
Diab Care 2007; 30: 
1212-1218 
Diabetes outpatient population reviewed from Jan 2005 to Jan 2006 
n=2392 (1974 with NAFLD; 418 without) 
 
US screening for NAFLD in the absence of excessive alcohol 
consumption and other causes of chronic liver disease 
 
CAD = MI, angina or revascularisation 
CVA = ischaemic stroke, recurrent TIA, carotid endarterectomy or 
carotid stenosis ≥ 70% on carotid Doppler 
PVD = rest pain or claudication by echo Doppler, or lower extremity 
amputation or revascularisation 
70% T2DM have NAFLD. Higher prevalence of CVD in 
NAFLD (p<0.001) despite adjusting for age and sex, BMI, 
smoking, diabetes duration, A1c, LDL-C, medications (OR 
approx 1.8 [95% CI 1.4-2.25]) 
 
Adjusting for metabolic syndrome and above variables, 
results remain significant (OR 1.6 [1.2-2.0], p=0.03)  
 
CAD 26.6% v 18.3% (= 1.45x increase) 
CVA 20.0% v 13.3% (= 1.5x increase) 
PVD 15.4% v 10% (= 1.54x increase) 
Targher et al. 
Diab Care 2007; 30: 
2119-2121 
Valpolicella Heart Diabetes Study subjects; 6.5 year follow-up 
T2DM patients attending diabetes clinics 
n=2103 (157 with NAFLD; 1946 no NAFLD)  
 
US screening for NAFLD in the absence of other causes of chronic liver 
disease but 10% drank >20g ethanol/day. 
 
Cardiovascular event = non-fatal MI or revascularisation, non-fatal 
CVA or cardiovascular death 
384 had CV events; 96 of 384 had NAFLD 
NAFLD association with incident CVD = HR 2.01 (95% CI 
1.4-2.9; p<0.01) 
 
After adjusting for age, sex, smoking, diab duration, A1c, 
LDL and medications – HR 1.96 (1.4-2.7, p<0.001) 
 
Adjusting for above and metabolic syndrome – HR 1.87 
(1.2-2.6, p<0.001) 
Hamaguchi et al. 
WJG 2007; 13: 1579-
1584 
Follow-up of healthy workers on routine company medical checkups 
after approx. 5.8 years  
n=1221 (231 with NAFLD; 990 no NAFLD); 426 were lost to follow-up 
US screening for NAFLD in the absence of excessive alcohol 
consumption and other causes of liver disease 
Endpoint: First cardiovascular event (unstable angina, acute MI, silent 
MI, ischaemic stroke, cerebral bleed) 
12 cardiovascular events in those with NAFLD and 10 
events in those without NAFLD  
NAFLD significantly assoc with CVD independent of 
conventional RFs (age, smoking, SBP and LDL) – OR 3.57 
(95% CI 1.47-8.67, p=0.005) 
 
Independent of risk factors and metabolic syndrome OR 
4.12 (95% CI 1.58-10.75, p=0.004) 
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Authors Study details Results 
Lizardi-Cervera et al. 
Dig Dis Sci 2007; 52: 
2375–2379 
Healthy company workers, routine medical checkups in Mexico City 
n=936 (301 with NAFLD and 635 controls) 
 
US screening for NAFLD in the absence of excessive alcohol 
consumption and viral hepatitis 
 
CVD risk calculated based on bivariate model described by Ridker 
using hsCRP and LDL-C 
 
 
Mean concentration of uCRP was higher in subjects with 
HS (4.50 vs. 2.79 mg/L; P<0.001) 
 
The relative risk for cardiovascular disease was significantly 
higher for subjects with NAFLD (OR 4.7 v 2.8; P<0.05) [i.e. 
1.68x higher] 
Wong et al. 
Gut 2011; 60: 1721-1727 
Patients undergoing elective coronary angiograms 
Mean follow-up 87 ± 22 wks 
n=612 (356 with NAFLD; 256 without NAFLD) 
 
US screening for NAFLD in the absence of excessive alcohol intake and 
other causes of fatty liver 
 
Significant coronary artery disease (CAD) = ≥50% stenosis in at least 1 
coronary artery 
 
Endpoint: CV deaths, non-fatal MI and need for further 
revascularisation at follow-up 
 
NAFLD more prevalent in those with CAD than without 
(64.7% v 37.4%, p<0.001) 
301 patients with NAFLD had significant CAD versus 
164 patients without NAFLD (85% v 64%) (p<0.001) 
 
Univariate analysis: NAFLD increased risk of CAD 3.07 (2.09 
to 4.51) <0.001 
Mutivariate analysis: NAFLD independent factor associated 
with CAD – OR 2.31 (95% CI 1.46-3.64, p<0.001) after 
adjusting for demographic and metabolic factors. 
 
No increased risk of developing endpoint in NAFLD 
(adjusted HR 0.89; 95% CI 0.49 to 1.60; p=0.70)  
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Table 1.4: Studies on cardiovascular mortality in patients with NAFLD (9,11,84)  
Paper Study detail Result 
Ekstedt et al. 
Hepatology 2006; 44: 
865-873 
 
Biopsy proven NAFLD 
n=129 at baseline with 88 participating in follow-up 
Mean follow-up of 13.7 ± 1.3 years 
71 patients with NASH, 12 with steatosis and non-
specific inflammation and 46 with simple steatosis 
 
Increased cardiovascular-related death in NASH patients 
compared with reference population – 15.5% v 7.5%, 
p=0.04 
 
No survival difference in patients with steatosis 
Soderberg 
Hepatology 2010; 51: 
595-602 
 
Biopsy proven NAFLD  
n=256 patients with raised transaminases; of these 118 had NAFLD 
Mean follow-up of 21 ± 7.7 years 
 
 
51 NASH and 67 simple steatosis 
 
Compared with population adjusted for age, sex and 
calendar period: NAFLD had increased all-cause 
mortality SMR 1.69, 95% CI 1.24-2.25  
Simple steatosis: SMR 1.6, 95% CI 0.98-2.32 (p=0.062) 
NASH: SMR 1.9 95% CI 1.19-2.76 (p=0.007) 
 
CVD leading cause of death (30%) 
Dunn 
Am J Gastroenterol 
2008; 103: 2263-2271 
 
Participants from Third National Health and Nutrition Examination 
Survey (NHANES III)  
Suspected NAFLD based upon unexplained raised ALT (ALT > 30 for 
men, ALT > 19 for woman) 
Absence of excessive alcohol intake and other causes of chronic liver 
disease 
980 with suspected NAFLD, 6594 without  
Mean follow-up of 8.7 years 
Increased all cause mortality [HR 4.10, 95% CI 1.27-
13.23] and cardiovascular mortality [HR 8.15, 95% CI 2.0-
33.2] after adjusting for age, gender, SBP, DBP, waist 
circumference, total cholesterol, HDL, triglycerides, 
smoking, CRP, daily alcohol, physical activity, diabetes 
and use of HMG-CoA reductase inhibitor 
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VSL#3 Probiotic 
Probiotics are non-pathogenic live micro-organisms which are beneficial to gut 
health. A number of human studies using various types of probiotics have 
shown improved lipid profile (85–88), reduced systolic blood pressure (85,87), 
improved insulin sensitivity (89), increased antioxidant activity (90) and 
decreased inflammation (91).  
 
VSL#3 contains 8 different strains of live freeze-dried lactic acid bacteria: 
streptococcus thermophilus, bifidobacterium breve, bifidobacterium longum, 
bifidobacterium infantis, lactobacillus acidophilus, lactobacillus plantarum, 
lactobacillus paracasei and lactobacillus bulgaricus. It is a highly concentrated 
probiotic product with 450million bacteria per sachet. It is classed as a food 
supplement within the definition of Directive 2002/46/EC of the European 
Parliament and of the Council of 10 June 2002 on the approximation of the laws 
of the Member States relating to food supplements.  
 
Studies exploring the effects of VSL#3  on biophysical markers of insulin 
resistance, vascular inflammation, oxidative stress, endothelial dysfunction and 
liver injury are, thus far, limited and mainly based on animal models. In the 
following sections, the effects of VSL#3 on each of these markers will be 
discussed.  
 
VSL#3 and insulin resistance 
Li et al. [2003] examined the effects of VSL#3 and anti-TNF antibodies in 
genetically obese mice (ob/ob). VSL#3 inhibited hepatic JNK and NF- κB activity 
suggesting treatment improves hepatic insulin sensitivity (92). Although insulin 
sensitivity was not physically measured in the study, it is known that activation 
of JNK and NF- κB pathways promotes insulin resistance so it is reasonable to 
deduce VSL#3 improves insulin sensitivity via inhibition of these pathways. 
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Ma et al. [2008] demonstrated depletion of hepatic natural killer T (NKT) cells in 
mice fed with a high fat diet (HFD). NKT cells balance the production of pro-
inflammatory and anti-inflammatory cytokines. Treatment with VSL#3 
improved insulin sensitivity by increasing hepatic NKT cells which was 
associated with reduced TNFα expression and inhibition of IKK-β activity (93).  
 
Mencarelli et al. [2012] treated mice models of atherosclerosis, hyperlipidaemia 
and steatosis (ApoE-/-) with dextran sulphate sodium (DSS; induces gut 
inflammation) and/or VSL#3. DSS-treated mice had low grade intestinal 
inflammation with increased gut permeability, mesenteric adiposity, insulin 
resistance, progressed from steatosis to steatohepatitis, and had more severe 
atherosclerotic lesions in the aorta. VSL#3 reduced insulin concentration and 
improved insulin signalling in the liver and adipose tissue (94). Other effects of 
VSL#3  in this study are described in relevant sections below. 
 
In healthy overweight adults treated with VSL#3, there was significant 
improvement in insulin sensitivity. Insulin resistance was associated with 
significantly lower lactobacilli and bifidobacteria count, and higher 
concentrations of E. coli and bacteroides. Modification of gut flora with 
probiotics improved insulin sensitivity supporting the role of gut microbiota in 
driving insulin resistance (95).  
 
VSL#3 and vascular inflammation 
Rajkumar et al. [2014] evaluated serum hsCRP and proinflammatory markers in 
overweight individuals and found a significant decrease in hsCRP but only a 
modest reduction in TNFα, IL-6 and IL-1β following VSL#3 treatment (95). 
Sanaie et al. [2013] demonstrated a significant reduction in hsCRP in critically ill, 
enterally-fed patients treated with VSL#3 compared with placebo (96).  
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VSL#3 and oxidative stress 
In mice fed a HFD and treated with VSL#3, there was a significant decrease in 
hepatic markers of lipid peroxidation (malondialdehyde) and oxidative stress 
(inducible nitric oxide synthase and 3-nitrotyrosine) compared to mice on HFD 
only (97). 
 
Loguercio et al. [2005] assessed the effects of VSL#3 in patients with various 
chronic liver diseases including NAFLD  and revealed a significant reduction in 
plasma markers of lipid peroxidation (malondialdehyde and 4-hydroxynonenal) 
and oxidative stress (S-nitrosothiols) (98).  
 
VSL#3  and endothelial dysfunction 
Mencarelli [2012] reported severe aortic plaque disease in DSS-treated ApoE-/- 
mice. Treatment with VSL#3 reduced plaque development and decreased 
aortic levels of inflammatory mediators such as ICAM-1 (intercellular adhesion 
molecule-1), VCAM-1 (vascular cell adhesion molecule-1) and RANTES 
(regulated on activation, normal T cell expressed and secreted) (94).  
 
Rashid et al [2014] assessed the effects of VSL#3 on endothelial dysfunction in 
an animal model of biliary cirrhosis and portal hypertension. VSL#3 improved 
endothelium-derived hyperpolarisation (EDH)-mediated relaxation to 
acetylcholine in mesentery artery rings and this was associated with reduced 
arterial wall oxidative stress, reduced local vascular angiotensin activation and 
decreased circulating proinflammatory cytokines (99).  
 
No human studies in this area have been reported so far. 
 
VSL#3  and liver injury 
Mencarelli et al. [2012] reported that VSL#3 reversed histological progression 
of liver inflammation and fibrosis (but not steatosis) with associated decrease in 
inflammatory mediators (TNFα, ICAM-1, RANTES and  macrophage 
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inflammatory protein-1α) within the liver (94). Anti-inflammatory effects of 
VSL#3 in mice models may be partly due to modulation of NF-κB pathway (97). 
Similar histological findings were seen in ob/ob mice treated with VSL#3 (92). 
In contrast, another study showed significant improvement in hepatic steatosis 
following VSL#3 treatment in mice fed a high fat diet (93). 
 
Several animal studies have shown significant decrease in ALT and/or AST levels 
after VSL#3 treatment (92,94,97,98). Experiments in the methionine-choline-
deficient diet–induced mouse model of NASH demonstrated significant anti-
fibrotic effects in animals fed VSL#3 (100).  
 
In obese children with biopsy proven NAFLD, VSL#3 improved ultrasound-
defined liver steatosis and reduced BMI. Glucagon like peptide-1 (GLP-1) was 
raised so it was speculated that VSL#3-dependent GLP-1 rise may contribute to 
positive effects of VSL#3 (101). A small study on 8 patients with liver cirrhosis 
treated with VSL#3  illustrated a non-significant reduction in plasma 
endotoxaemia (102). Two other studies supported reductions in endotoxin 
levels with improvement in liver prognosis score when patients with cirrhosis 
were treated with different probiotic strains (103,104). 
 
Summary 
Patients with NAFLD have increased risk of developing CVD beyond established 
cardiovascular risk factors and a proportion of them progress to more severe 
forms of liver disease. Unsurprisingly, NAFLD is associated with significant 
cardiovascular and liver-related morbidity and mortality. It is debatable 
whether fatty liver is the source that drives atherosclerosis or merely a target 
organ of obesity-related inflammation and insulin resistance.  
 
Being closely linked with obesity and type 2 diabetes, NAFLD is rapidly 
becoming a major public health issue worldwide. At present, there is no proven 
cure for NAFLD and treatment is based on weight loss and addressing 
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cardiovascular risk factors. Gut microbiota is considered a potential therapeutic 
target to treat this condition. Existing data on the use of probiotic 
supplementation in patients with NAFLD is sparse, particularly its effects on 
cardiovascular risk markers.  
 
VSL#3 probiotic seems a promising therapy for NAFLD with beneficial effects 
attained through modification of gut microbiota, displacement of pathogenic 
strains of SIBO, reduction in gut-derived endotoxinaemia, reduction in 
inflammation and improvement in insulin sensitivity. This may alleviate liver 
damage and stop the progression of liver disease, and improve overall 
cardiovascular risk profile. 
 
Hypotheses and Aims 
The primary aim of this study is to examine the hypothesis that: 
(i) VSL#3 improves markers of oxidative stress, inflammation, endothelial 
function and insulin resistance in patients with NAFLD. 
(ii) VSL#3 improves markers of liver injury in the same patients. 
 
The secondary aims are: 
(i) To test the hypothesis that insulin resistance, oxidative stress, 
endothelial function, vascular inflammation and liver injury are 
interdependent. 
(ii) To explore the possibility of identifying a primary outcome measure 
which can be used in future definitive studies as this is an exploratory 
study without a primary outcome measure. 
 
This study will add further information to currently limited literature on the 
effects of VSL#3 probiotic supplementation in patients with NAFLD. Should the 
hypotheses be proven, larger clinical trials ought to be conducted to confirm 
that VSL#3 confers an overall improvement in cardiovascular risk and reduce 
the progression of liver injury in patients with NAFLD.  
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Methods 
Trial Design 
This is a randomised, double-blinded, placebo-controlled, proof-of-concept 
study to assess the effects of VSL#3 probiotics supplementation on endothelial 
function, oxidative stress, inflammation and insulin sensitivity in individuals 
with NAFLD.  
 
Participants 
Potentially suitable participants were identified from Hepatology and Diabetes 
clinics, and the Radiology department at Queen Alexandra Hospital (QAH), 
community-based obesity clinic and Primary Care in Portsmouth. 
Correspondence, including a patient information sheet, was sent to these 
individuals with the option to consider participating in the study by means of a 
reply slip. Prospective participants are screened for eligibility via a face-to-face 
interview. 
 
The diagnosis of NAFLD was defined by evidence of fatty infiltration of the liver 
on abdominal ultrasound, the absence of secondary cause of liver disease by 
means of a biochemical liver screen (viral hepatitis screen, autoimmune profile, 
ferritin, caeruloplasmin [only individuals under the age of 50], and alpha-1 
antitrypsin) and the absence of excessive alcohol consumption (≤21 units per 
week in men and ≤14 units per week in women) (14).  
 
Participants eligible for this study were patients with confirmed NAFLD (either 
biopsy proven or based on imaging), age between 18 and 70 years, HbA1c less 
than 86mmol/mol (10%), and at least 20% risk of a cardiovascular event over 
the next 10 years. Cardiovascular risk was calculated using the Qrisk2 score 
which factors in age, sex, ethnicity, UK postcode, smoking status, diabetes 
status, family history of angina or myocardial infarction in first degree relatives 
under the age of 60, blood pressure treatment, presence of atrial fibrillation, 
chronic kidney disease or rheumatoid arthritis, cholesterol/HDL ratio, systolic 
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blood pressure, height and weight (105). Existing cardiovascular risk algorithms 
do not include NAFLD and this may underestimate the risk of cardiovascular 
disease. Qrisk2 score was multiplied by a factor of 1.87 to reflect the effect of 
NAFLD on cardiovascular risk (81).  
 
Exclusion criteria were established cardiovascular disease (defined as ischaemic 
heart disease, cerebrovascular disease or peripheral vascular disease), 
decompensated liver cirrhosis determined by the presence of encephalopathy, 
ascites, variceal bleed and jaundice (106), allergy or intolerance to VSL#3 
probiotic, chronic excess alcohol intake (>21units per week for men and 
>14units per week for women in the last 2 years) (107), antibiotic treatment 4 
weeks prior to the study and/or more than 3 courses of antibiotic treatment 
over the preceding 6 months (104), solid organ or bone marrow transplantation 
and oral steroid therapy. An electrocardiogram was performed at the screening 
visit to rule out incidental findings suggestive of ischaemic heart disease. 
 
Written informed consent was obtained from all eligible participants. Ethical 
approval for the study was sought and granted by NRES Committee South 
Central – Southampton B (REC ref: 11/SC/0532). 
 
Clinical protocol 
This was a 10-week, randomised, double blinded, placebo-controlled study 
conducted at the Diabetes Centre, QAH. Figure 2.1 summaries the study design. 
Each subject attended 2 study visits having fasted for at least 12 hours prior to 
the visit. Subjects on insulin therapy were asked to omit insulin dose(s) the day 
before their visit (i.e. at least 12 hours before the visit and no Lantus 
administration 24 hours before the visit) and not to smoke or exercise 30 
minutes on the day of their visit (Appendix 1). They were also asked not to 
consume other probiotic products during the study period. 
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Figure 2.1: Schematic Diagram of Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At the first visit, a clinical history and routine physical examination was 
undertaken. Body weight was measured using a digital column scale (Seca; 
model 778) without shoes and wearing light clothing only. Waist circumference 
was measured midway between the bottom of the ribs and the top of the pelvic 
bone. Metabolic parameters measured were systolic and diastolic blood 
pressure, HbA1c, fructosamine, total cholesterol, HDL cholesterol, LDL 
cholesterol and triglycerides.  
Visit 1 
Physical examination 
Urine sampling, blood sampling, lactulose hydrogen breath test, 
photoplethysmography and ASQ liver imaging 
Randomisation 
2 sachets VSL#3 twice daily   
for 10 weeks 
Placebo equivalent twice daily 
for 10 weeks 
Visit 2  
Urine sampling, blood sampling, lactulose hydrogen breath test, 
photoplethysmography, and ASQ liver imaging 
Assessment of suitability, Recruitment, “Patient information leaflet” 
supplied, ECG, and Consent obtained 
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At each visit, subjects had their blood pressure measured with an automated 
sphygmomanometer (Welch Allyn; 52000 series) after sitting quietly in a stress-
free environment for at least 5 minutes (British Hypertension Society).  
 
Fasting venous blood samples were taken to measure insulin resistance, lipid 
profile (total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides), 
glycaemic control (HbA1c and fructosamine), liver enzymes (ALT and AST), 
markers of synthetic liver function (albumin and INR), and  platelet count (for 
calculation of fibrosis risk score). Analyses of these measurements were 
undertaken at the Department of Blood Sciences, QAH, with the exception of 
fructosamine which was analysed at the Department of Biochemistry, Royal 
United Hospital, Bath. 
 
Additional venous blood samples for markers of endothelial function and 
oxidative stress were obtained for analysis at the School of Pharmacy and 
Biomedical Sciences, University of Portsmouth. The coefficient of variation for 
these tests was <10%. Venous blood samples for hsCRP were analysed at the 
Department of Chemical Pathology/Metabolic Medicine, Guys and St Thomas’ 
Hospital, London. A subset of subjects had liver ultrasound using Acoustic 
Structural Quantification (ASQ) at the Radiology Department, QAH. 
Methodologies for analyses of these blood samples, digital 
photoplethysmography and ASQ are described below. 
 
Having obtained all fasting venous blood samples, a lactulose hydrogen breath 
test (LHBT) was performed to detect the presence of small intestinal bacterial 
overgrowth (108,109). Hydrogen breath test protocols are highly 
heterogeneous with multiple definitions of a positive test (110). In this study, a 
baseline breath sample was collected (Micro meter H2, Micro Medical 
Rochester, Kent, UK) prior to the administration of lactulose solution (10g in 
200ml of water). Further breath samples were taken every 20 minutes for 3 
hours (111). An increase in hydrogen concentration of more than 20 parts per 
million from baseline within 90 minutes of the test and a second peak at least 
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15 minutes following the initial peak constitute a positive LHBT (108,109).  All 
subjects were asked to avoid foods high in fibre and starch (apart from rice) the 
day before their visit for the purpose of the LHBT. 
 
Study measurements were undertaken at the beginning and the end of the 
intervention period. At the end of the first visit, subjects were randomly 
assigned to receive either VSL#3 probiotic supplementation or its placebo 
equivalent. The dose of VSL#3 (or placebo) was 2 sachets twice a day for 10 
weeks. The rationale for using this particular dose and duration of VSL#3 is 
discussed in the ‘Discussion’ section under ‘Dose and Duration of VSL#3’. Both 
participants and the study team were blinded to the intervention assigned.   
 
In terms of the study methodology, I carried out the recruitment of participants, 
the venous sampling, the digital photoplethysmography, the lactulose hydrogen 
breath test, and the bench analyses of biomarkers of oxidative stress and 
endothelial function. The latter analyses were performed under the supervision 
of Dr David Laight. 
 
 
 
Insulin Resistance 
Homeostasis Model Assessment  
Background 
Several direct and indirect methods of measuring insulin resistance have been 
developed with hyperinsulinaemic euglycaemic clamp study considered the 
gold standard test (112,113). However, this method is time consuming, labour-
intensive and technically challenging therefore limiting its use. Homeostasis 
model assessment (HOMA) is a surrogate marker of insulin resistance and has 
been extensively used as a predictor of insulin resistance in epidemiological and 
clinical studies (114).  
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HOMA was first described in 1985 based on a mathematical model to predict 
insulin resistance and beta-cell function from steady-state plasma glucose and 
insulin concentrations (115). The updated HOMA2 (1996) is a computer-based 
model which takes into account variations in hepatic and peripheral glucose 
resistance as well as renal glucose losses; and allows the use of total and 
specific insulin assays. There is good correlation between estimates of insulin 
resistance derived from HOMA and euglycaemic clamp studies in patients with 
dysglycaemia and normal glucose tolerance (114). HOMA has also been used to 
predict insulin resistance in patients with NAFLD (116). The HOMA2 calculator 
(Figure 2.2), introduced in 2004, provides easy access to generating estimates of 
insulin sensitivity and beta-cell function based on the HOMA2 model 
(downloadable at https://www.dtu.ox.ac.uk/homacalculator/).  
 
Technique 
Three paired fasting venous glucose and insulin were taken at 5-minute 
intervals from study subjects. Obtaining 3 samples provide more accuracy in 
assessing real-time glucose and insulin levels compared with a single sample 
alone (114). Glucose samples were analysed at the Department of Blood 
Sciences, QAH, and insulin samples were frozen immediately and analysed at 
the Department of Chemical Pathology, University Hospital Southampton. The 
mean glucose and insulin values were entered into the HOMA2 calculator to 
obtain HOMA-IR estimates.  
 
In this study, subjects on exogenous insulin therapy were included as the use of 
HOMA to estimate insulin resistance and beta cell function has been reported 
previously  (117–119). 
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Figure 2.2: HOMA2 calculator 
 
(https://www.dtu.ox.ac.uk/homacalculator/) 
 
 
Endothelial Function 
The endothelium is a major regulator of vascular homeostasis, maintaining a 
balance between endothelium-derived vasoconstricting and relaxing factors. 
Damage to the endothelium (e.g. from cardiovascular risk factors such as 
diabetes, smoking, hypertension and hyperlipidaemia) results in an imbalance 
of vasoconstricting and relaxing factors which lead to processes that promote 
atherosclerosis. The earliest changes that precede the formation of 
atherosclerotic lesions occurring in the endothelium include increased 
endothelial permeability, upregulation of endothelial adhesion molecules (such 
as VCAM-1, ICAM-1 and E-selectin), upregulation of leucocyte adhesion 
molecules (such as  L-selectin, integrins and platelet-endothelial-cell adhesion 
molecule 1) and the migration of leucocytes into arterial wall (120).  
 
Nitric oxide (NO) is an endothelium-derived relaxing factor which plays a pivotal 
role in controlling vascular tone and vasomotor function. NO is formed from the 
enzymatic action of endothelial nitric oxide synthase (eNOS) on L-arginine, in 
the presence of co-factors such as tetrahydrobiopterin and nicotinamide 
adenine dinucleotide phosphate (NADPH). NO stimulates guanylyl cyclase in 
vascular smooth muscle to produce cyclic guanosine monophosphate (cGMP) 
which causes vasodilatation. Apart from vasodilatation, NO inhibits leucocyte 
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adhesion, platelet aggregation and proliferation of vascular smooth muscle 
cells. Impaired NO-mediated endothelium-dependent vasodilatation is 
considered the hallmark of endothelial dysfunction, an early sign of 
atherosclerosis (121,122).  
 
In this study, several techniques were used to measure endothelial function.  
 
Digital photoplethysmography 
Background 
The most widely used clinical endpoint to assess endothelial function is 
endothelial dependent vasodilatation following stimulation of endothelial NO 
release by pharmacological agents (123). One of the earliest techniques 
involved cardiac catheterisation and direct assessment of the coronary 
circulation by measuring the change in coronary artery diameter following local 
infusion of vasoactive agents such as acetylcholine (124,125). This method is 
invasive limiting its use in general. Endothelial dysfunction is a systemic process 
with impaired endothelial responses seen in peripheral circulation and this has 
led to the development of less invasive methods of assessing endothelial 
function. These include flow-mediated dilatation (FMD; measures changes in 
brachial artery diameter using ultrasound), forearm perfusion technique 
(measures changes in forearm blood flow using strain gauge plethysmography), 
pulse wave analysis (discussed below) and laser Doppler flowmetry of the skin 
(measures microvascular endothelial function of the skin) (123,126). Of these 
methods, forearm perfusion studies would still be considered invasive as it 
requires brachial arterial cannulation for local infusion of vasoactive drugs. 
 
In patients with NAFLD, assessment of endothelial function using FMD (66,68), 
strain gauge plethysmography (69) and pulse wave analysis (70) have been 
described. 
 
Pulse wave analysis is an assessment of arterial stiffness based on arterial pulse 
waveform. Endothelial function can be determined by changes in the peripheral 
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pressure waveform in response to β-adrenergic stimulation as measured by 
radial artery tonometry and quantified using the augmentation index(127). 
Another means of assessing the pulse wave is based on measuring the digital 
volume pulse (DVP) using finger photoplethysmography (pulse contour 
analysis). Whilst the amplitude of the pulsatile component of the DVP is by 
factors that influence local perfusion such as respiration and the sympathetic 
nervous system, the contour of the pulse remains fairly unchanged. Instead, the 
contour of the DVP is primarily influenced by characteristics of the systemic 
circulation (128).  
 
Dawber et al. measured the DVP of 1778 individuals from the Framingham 
cohort and suggested that DVP is categorised into 4 classes (Figure 2.3). Class I 
is seen in young healthy individuals whereas Class IV in older people and those 
with established cardiovascular disease (129). 
 
Figure 2.3: Classification of the digital volume pulse (129) 
 
 
Class I: A distinct notch is seen on the downward slope of the pulse wave 
Class II: No notch develops but the line of descent becomes horizontal 
Class III: No notch is present but a well-defined change in the angle of descent is observed 
Class IV: No evidence of a notch is seen or no change in angle of descent occurs. 
 
There are two parts to the waveform - the systolic component of the DVP arises 
from a forward-going pressure wave transmitted from the heart (left ventricle) 
to the finger, and the diastolic component arises from a pressure wave 
reflected backward from peripheral arteries mainly in the lower body which 
then propagates to the finger. The reflection index (RI) is calculated as a ratio of 
the reflected wave to the first peak and changes in RI in response to vasoactive 
Class I Class II Class III Class IV 
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drugs can be used to determine endothelial function. For example, 
Chowienczyk et al. (1999) evaluated changes in RI following the administration 
of Salbutamol (endothelium-dependent vasodilator) and glyceryl trinitrate 
(endothelium-independent vasodilator) in patients with uncomplicated T2DM. 
Changes in RI was blunted following Salbutamol but preserved after GTN 
administration. As T2DM is associated with impaired endothelial-dependent 
vasodilation, the authors suggest using changes in RI in response to Salbutamol 
as a means of assessing endothelial function (130). 
 
Figure 2.4: Reflection index 
 
 
Technique 
Subjects were asked to lay on their back in a quiet room for at least 15 minutes 
prior to the test. A pulse trace probe was placed onto the index finger and 
measurements were obtained whilst subjects laid still and relaxed (Micro 
Medical Pulse Trace, Rochester, Kent, UK). Three baseline reflective index (RI) 
readings were taken 5 minutes apart followed by the administration of 400mcg 
sublingual glycerol trinitrate (GTN; an endothelium-independent vasodilator). 
Subsequent RI readings were taken at 3 and 5 minutes after GTN. There was a 
washout period of 30 minutes, after which 3 baseline RI readings were taken 5 
minutes apart to ensure RI values have returned to baseline.  Inhaled 
Salbutamol 400mcg (an endothelium-dependent vasodilator) was then 
administered via a spacer device and RI readings were taken at 10, 12 and 15 
minutes after Salbutamol inhalation. The mean of the RI readings at baseline, 
post-GTN and post-Salbutamol was calculated and based on these values; the 
change in RI was calculated for GTN (∆RI-GTN) and Salbutamol (∆RI-Salb) to 
a 
b 
Reflection index (%) = b/a x 100 
 
‘b’ is the reflected wave from the lower body to 
the finger and ‘a’ is the transmitted wave from 
the heart to the finger. 
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determine endothelium-independent and dependent vasodilator changes 
respectively (130). 
 
sVCAM-1 
Background 
Vascular cell adhesion molecule-1 (VCAM-1) is a member of the 
immunoglobulin superfamily of endothelial adhesion molecules. VCAM-1 is 
expressed on endothelial cells and mediates leucocyte adhesion to the 
endothelium with subsequent transendothelial migration, a key step in the 
formation of atherosclerotic lesions (120). Animal experiments demonstrated 
upregulation of VCAM-1 expression in atherosclerotic lesions supporting the 
role of VCAM-1 in early atherosclerosis (131,132). VCAM-1 has been found in 
human atherosclerotic plaque but was more prevalent in intimal 
neovasculature and nonendothelial cells, and this was associated with increased 
leucocyte recruitment (133). Soluble VCAM-1 (sVCAM-1) has been used as 
predictor of cardiovascular risk in a number of clinical studies (134–137). 
 
Technique 
4ml of venous blood were collected in an EDTA (Ethylenediamine tetraacetic 
acid) bottle and centrifuged at 1000g for 15 minutes. The plasma supernatant 
was extracted and stored at -80oC. sVCAM-1 was measured using the 
Quantikine Human sVCAM-1 immunoassay kit purchased from R&D Systems. 
The assay employs the quantitative sandwich enzyme immunoassay technique. 
All reagents were prepared according to manufacturer’s kit instructions. A 96-
well plate coated with mouse monoclonal antiboby against human sVCAM-1 
was used. Thawed plasma supernatant was diluted 20-fold with Calibrator 
Diluent RD5P (buffered protein solution). 100l of sVCAM-1 Conjugate 
(monoclonal antibody against sVCAM-1 conjugated to horseradish peroxidase) 
and 100l of diluted sample were added to each well. This was incubated for 
1.5 hours at room temperature. Wells were then aspirated and washed four 
times with Wash Buffer (solution of buffered surfactant). 100l of Substrate 
Solution (50:50 mix stabilised hydrogen peroxide and chromogen) was added to 
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each well and incubated, protected from light, for 20 minutes at room 
temperature. 50l Stop Solution (2 N sulfuric acid) was added to each well to 
stop the reaction. The optical density was measured using a microplate reader 
set at 450nm with wavelength correction set at 540nm. All samples were 
analysed in duplicate and the mean value was calculated. The mean and range 
of sVCAM-1 in healthy volunteers were 531ng/ml and 341-897ng/ml 
respectively. 
 
cGMP 
Background 
Nitric-oxide induced endothelial smooth muscle relaxation is mediated through 
the activation of guanylyl cyclase and formation of cyclic guanosine 
monophosphate (cGMP) (138). Thus, measuring cGMP indirectly quantify 
endothelial nitric oxide bioactivity. Several studies have demonstrated a 
reduction in plasma cGMP levels associated with improved endothelial function 
after anthocyanin supplementation (anthocyanin-rich food can activate eNOS) 
in patients with hypercholesterolaemia (139), after Benipine (calcium channel 
blocker) in individuals with coronary vasospasm (140), and after vitamin B12 
and folate supplementation in patients with metabolic syndrome (141). 
 
Technique 
4ml of venous blood were collected in an EDTA bottle and centrifuged at 1000g 
for 15 minutes. The plasma supernatant was extracted and stored at -80oC. 
cGMP is measured using the cGMP Assay kit purchased from R&D Systems. The 
assay is based on a competitive binding technique in which human cGMP 
competes with a fixed amount of horseradish peroxidase (HRP)-labeled cGMP 
for sites on a rabbit polyclonal antibody. All reagents were prepared according 
to manufacturer’s kit instructions. A 96-well microplate coated with a goat anti-
rabbit polyclonal antibody was used. Thawed plasma supernatant was diluted 
20-fold with Calibrator Diluent RD5-5 (buffered protein solution). 100l of 
diluted sample, 50l of cGMP Conjugate (cGMP conjugated to horseradish 
Peroxidise) and 50l of Primary Antibody Solution (rabbit polyclonal 
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antibody to cGMP) were added to the wells. The plate was then incubated and 
gently shaken at room temperature on a horizontal microplate shaker for 3 
hours. Wells were aspirated and washed four times with Wash Buffer (solution 
of buffered surfactant). 200l Substrate Solution (50:50 mixed stabilised 
hydrogen peroxide and stabilised chromogen) was added to each well and 
incubated for 30 minutes at room temperature protected from light. 50l Stop 
Solution (2 N sulfuric acid) was added to each well to stop the reaction. The 
optical density was measured using a microplate reader set at 450nm with 
wavelength correction set at 540nm. All samples were analysed in duplicate and 
the mean value was calculated. The mean and range of cGMP in healthy 
volunteers were 152pmol/ml and 75-219pmpl/ml respectively. 
 
Albumin Creatinine ratio 
Background 
Microalbuminuria is defined as urinary albumin excretion of 30-300mg in 
24hours. It has been established as an independent predictor of cardiovascular 
disease (142–144). Instead of quantifying urine albumin excretion in a 24hour 
urine collection, it can be calculated as the urine albumin:creatinine (ACR) ratio 
from a spot urine collection. The criteria for microalbuminuria as measured by 
ACR is 3-30mg/mmol and sex-specific range at the lower threshold of ACR can 
be applied with males >2.5mg/mmol and females >3.5mg/mmol (145).  
 
Technique 
Subjects collected an early morning urine sample on the day of their visit and 
provided the sample on attendance. This was analysed at the Department of 
Blood Sciences, QAH, Portsmouth. Urine albumin was measured by 
radioimmunoassay and urine creatinine concentration was measured by an 
end-point Jaffe reaction.  
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Oxidative Stress 
In the endothelium, excessive production of reactive oxygen species (ROS) in 
the presence of impaired and/or insufficient antioxidant defence mechanism 
leads to oxidative stress. Cardiovascular risk factors such as smoking, 
hypertension, hypercholesterolaemia and diabetes increase the expression 
and/or activity of NADPH oxidases (NOX) in the vascular wall leading to the 
formation of ROS such as hydrogen peroxide. These risk factors are also 
associated with uncoupling of eNOS causing production of ROS (hydrogen 
peroxide and superoxide). Xanthine oxidase is another potential source of ROS 
production, generating hydrogen peroxide and superoxide. Over time, chronic 
ROS production causes functional damage of eNOS such that it becomes an 
enzyme that predominantly generates superoxide at the expense of NO 
formation (122).   
 
In this study, markers of oxidative stress measured are blood glutathione 
(GSH:GSSG) ratio, plasma antioxidant capacity and plasma lipid hydroperoxides. 
 
Glutathione ratio 
Background 
Glutathione (GSH) is a tripeptide found in the cytosol of cells and is the most 
abundant non-protein thiol that defends against oxidative stress. GSH removes 
hydrogen peroxide, under the action of gluthathione peroxidase, and is 
converted to oxidised glutathione (GSSG). GSSG is subsequently reduced back 
to GSH by glutathione reductase, at the expense of NADPH, forming a redox 
cycle. Severe oxidative stress overwhelms the ability to reduce GSSG to GSH 
resulting in the accumulation of GSSG. This leads to a depletion of GSH and a 
decrease in the ratio of GSH to GSSG (146).  The glutathione ratio (GSH:GSSG) is 
often used as an indicator of cellular redox state. Studies using GSH:GSSG as a 
marker of oxidative stress in patients with NAFLD have shown a reduction in 
GSH:GSSG (147,148). Ashfaq et al. (2006) suggested that glutathione redox 
state (expressed as Eh GSH/GSSG) is an independent predictor of early 
atherosclerosis in healthy adults (149). 
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Technique 
2ml of venous blood was collected into an EDTA bottle and mixed with 1ml 
0.5mM EDTA/10% (w/v) SSA (Sulphosalicylic acid). The sample was centrifuged 
at 1000-1500g for 15 minutes. The supernatant was extracted and stored at -
80oC. Glutathione ratio was assessed using the GSSG reductase/5,5’-dithio-
bis(2-nitrobenzoic acid) re-circulating method as originally described by Tietze 
[1969] (150) and more recently by Shaik and Mehvar [2006] (151). 
 
GSH was assessed photometrically in a microplate reader at 37° C. Thawed 
samples were diluted 1:20 with phosphate-buffered saline (PBS) (120mM, pH 
7.4). 70l of 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB) (0.857mM), 10l of 
diluted sample, 10l β-NADPH (5mM) and 10l GSH reductase (25units/ml) 
were added to each in a microplate. Reagents were dissolved in PBS + 6.3mM 
EDTA. The recirculating assay was initiated after incubation of 10 minutes at 
37°C by the addition of GSH reductase. The initial rate determined from the 
absorbance increase measured at 405nm every 10 seconds over 1 minute. 
For the selective measurement of GSSG (i.e. equivalent to 2 GSH), thiols were 
first derivatised with 1-methyl 2-vinylpyridine (M2VP) added to blood upon 
collection as described by Somparn et al. (2007) and thawed plasma were 
analysed following the steps above (152). 
 
All samples were analysed in duplicate, and the mean value was calculated and 
results were expressed as GSH:GSSG ratio. 
 
CUPRAC-BCS Assay 
Background 
Several methods have been developed to assess total antioxidant capacity 
(TAC), one being the cupric ion reducing antioxidant capacity (CUPRAC). This 
assay is based on the reduction of copper (II) complex by antioxidants. There is 
inconsistency in results using this assay which is related to the selected reaction 
time. Campos et al. (2009) have chosen to stop the reaction after 3 minutes by 
adding a strong chelating agent, bathocuproinedisulfonic acid disodium salt 
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(BCS) and suggested that the CUPRAC-BCS assay is a suitable method to assess 
TAC in heparinised plasma samples (153). 
  
Technique 
4ml venous blood was collected into a heparinised tube and spun in a 
centrifuged at 1000g for 15 minutes. Separated supernatant was extracted and 
stored in a plan tube at -80oC. 585l of 0.25mM BCS dissolved in 10mM PBS (pH 
7.4) was added to 15l of thawed sample. 200l of mixed sample was added to 
a 96-well plate in duplicate and the spectrophotometric absorbance (at 490nm) 
was measured (pre read). 50l Copper (II) Sulphate solution (0.5mM) was 
added to each well and incubated at room temperature for 3 minutes. 50l 
EDTA (10mM) was then added, which stopped further chemical reaction in 
vitro, and spectrophotometric absorbance (at 490nm) was re-measured (post 
read). The absorbance change due to reducing activity was calculated = (post 
read-pre read for sample) – (post read-pre read for ‘blank’).  
The steps above were repeated for graded dilutions of ascorbate to obtain a 
standard curve. Absorbance change was then converted into ascorbate 
equivalent antioxidant concentration (AEAC) based on linear regression. All 
samples were analysed in duplicate and the mean value calculated. 
 
Lipid Hydroperoxides 
Background 
Lipid peroxidation is a process in which ROS attack lipids resulting in the 
formation of lipid hydroperoxides (LHP). Quantification of LHP serves as a direct 
index of oxidative stress. In the PREVENT study, elevated LHP levels were 
predictive of future cardiovascular events in a cohort with angiographic 
evidence of CAD (154).  Ruiz et al (1997) described a method that measures LHP 
involving a coupled glutathione peroxidase–glutathione reductase reaction 
(155). 
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Technique 
4ml of venous blood were collected in an EDTA bottle and centrifuged at 1000g 
for 15 minutes. The plasma supernatant was extracted and stored at -80oC. 
Samples were thawed and butylated hydroxytoluene (BHT) solution (20mg/ml) 
was added at 1% of the sample volume, which stopped lipid peroxidation. 175l 
of TRIS base buffer (pH 7.6) was added to a 96-plate well. 50l of sample (mixed 
with BHT) was added to the wells and incubated at room temperature for 5 
minutes. 50l of bovine serum albumin (mimics plasma) was added to separate 
wells to act as the ‘blank’. Then, 50l of NADPH (2mmol/l), 10l of glutathione 
peroxidase (16kU/l) and 100l of reduced glutathione (4.25mmol/l) were 
added. The samples were incubated at 37oC for 15 minutes and 
spectrophotometric absorbance at 340nm was measured.  
 
50l of glutathione reductase (100kU/l) was added to samples, incubated at 
33oC for another 15 minutes and spectrophotometric measurement at 340nm 
was repeated. The difference between the two absorbances is proportional to 
the sample LHP content and the values were obtained by comparing with 
standards of t-butylhydroperoxide. 
 
 
Vascular Inflammation 
Highly-sensitive CRP 
Atherosclerosis is well recognised as an inflammatory condition (156). Highly-
sensitive C-Reactive Protein (hSCRP) is considered a cardiovascular risk 
predictor with cut-offs applied to the degree of cardiovascular risk i.e. <1mg/L 
as low risk, 1-3mg/L as moderate risk and >3mg/L as high risk (72).  
 
Technique 
2ml of venous blood was collected into a serum separation tube and allowed to 
clot for at least 30 minutes. The sample is then spun in a centrifuge (Heraeus 
Labofuge 200, Thermo Scientific, DJB Labcare, Bucks, UK) at 1000g for 15 
minutes. Serum was extracted and stored at -20oC for analysis at the 
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Department of Chemical Pathology/Metabolic Medicine, Guys and St Thomas’ 
Hospital, London. 
 
Liver Injury 
Acoustic Structural Quantification  
Background 
Acoustic Structure Quantification (ASQ, Toshiba Imaging Systems) is a novel 
high definition ultrasonographic modality that processes spatial echopatterns 
from scanned tissues. Unlike conventional ultrasonography, ASQ incorporates 
analysis of pure acoustical radiofrequency data in addition to “B” mode 
imaging, enabling measurement of fibrous structures that reflect the ultrasound 
beam. These parameters have been validated against liver biopsy of patients 
with Hepatitis C (157). ASQ scanning promises to be a useful non-invasive 
method of quantifying liver fibrosis, enabling larger areas of the liver to be 
accurately assessed.  
 
Technique 
A subset of subjects underwent ASQ liver scan (Toshiba Aplio XG) by two 
Radiologists at the Radiology Department, QAH, Portsmouth. Radiologists 
obtained images of regions of interest in the liver as per manufacturer’s 
manual. The mode, average and standard deviation of ASQ data were 
generated based on a statistical test (modified chi square) which is built into the 
software. The mode ASQ score (expressed as C2m) was used to compare the 
degree of liver fat/fibrosis instead of the average and standard deviation values 
as these can be affected by small vessels within the liver. 
 
Fibrosis risk score 
Background 
NAFLD fibrosis risk score and FIB4 index were discussed earlier in the 
‘Background’ section (Table 1.2). The former uses 6 variables (age, body mass 
index, AST/ALT ratio, platelet count and hyperglycaemia) to distinguish 
between patients with and without advanced fibrosis. The diagnostic accuracy 
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of this test was assessed in patients with NAFLD and achieved an AUROC of 0.82 
± 0.03 (95% CI = 0.76-0.88). By applying a low cutoff point (score < -1.455), only 
12% was incorrectly staged as absence of advanced fibrosis (a negative 
predictive value of 88%). By applying a high cutoff point (score > 0.676), 18% 
was incorrectly identified with advanced fibrosis (a positive predictive value was 
82%) (18) . 
 
FIB4 index uses 4 variables (age, aspartate transferase and aminotransferase 
levels, and platelet count) to identify patients with advanced fibrosis. In 
patients with NAFLD, the AUROC for diagnostic accuracy of this test was 0.802 
(95% CI 0.758-0.847). A FIB4  1.30 had a 90% negative predictive value and a 
FIB4 ≥ 2.67 had a 80% positive predictive value (19). 
 
Technique 
NAFLD fibrosis risk score can be calculated using the equation below: 
-1.675 + 0.037 × age (years) + 0.094 ×BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, 
no = 0) + 0.99 × AST/ALT - 0.013 × platelet count (× 109/L) - 0.66 × albumin 
(g/dL) 
 
Alternatively, an online calculator (nafldscore.com) can be used to generate a 
score based on the equation above. A score of > 0.676 predicts the presence of 
significant fibrosis (stage F3-F4 fibrosis); < 1.455 predicts the absence of 
significant fibrosis (F0-F2 fibrosis); and between these two cut-offs, it cannot be 
determined whether significant fibrosis exists. 
 
FIB4 index can be calculated using the equation below: 
Age (years) x AST (iu/l) / platelet count (109/L) x √ ALT (iu/l) 
 
A score of > 2.67 predicts the presence of advanced fibrosis (stage F3-F4 
fibrosis); < 1.30 predicts the absence of advanced fibrosis (F0-F2 fibrosis); and 
between these cut-offs, the score is indeterminate.  
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Outcomes 
Primary outcome 
The primary outcome of the study is to detect changes in markers of: 
 insulin resistance 
 oxidative stress 
 endothelial dysfunction 
 vascular inflammation 
 liver injury 
 
Secondary outcomes 
The secondary outcomes are to explore whether a primary outcome measure 
can be identified for use in future definitive studies; and define whether there is 
any relationship between insulin resistance, oxidative stress, endothelial 
function, vascular inflammation and liver transaminases at baseline. 
 
Sample size 
During the design of the study, input was sought from a Statistician (Mr Reuben 
O’Gollah) at the Research Office, QAH, to ascertain a sample size. As there were 
no clinical human studies assessing the effects of VSL#3 on biomarkers of 
endothelial dysfunction, oxidative stress, insulin sensitivity and inflammation in 
patients with NAFLD as described in this study, it was not possible to identify a 
primary outcome measure from the existing literature which would allow for a 
sample size calculation. Consequently, through discussions with Mr O’Gollah, 
this study was regarded as an exploratory proof-of-concept study. 
 
Randomisation 
Subjects were randomised in a 1:1 ratio between the treatment and placebo 
arms by a computer-generated code using random permuted blocks of 
randomly varying size. Two stratifying variables were used for randomisation – 
biopsy (with or without) and gender (male or female). As the study recruits both 
biopsy and non-biopsy proven NALFD individuals, stratification should ensure 
 
 
54 
 
equal allocation of biopsy-proven NAFLD participants in each treatment group. 
Randomisation was undertaken by the Clinical Trials Pharmacy Service, QAH at 
the time of dispensing the study product. 
 
Blinding 
Investigators and study subjects were blinded to the intervention throughout 
the study period. VSL#3  and placebo were supplied by VSL#3 Pharmaceuticals, 
Italy directly to the Clinical Trials Pharmacy Service, QAH who were responsible 
for packaging boxes containing identical, non-identifiable sachets of VSL#3 and 
placebo.  
 
Statistical analysis 
All analyses were treated as preliminary and exploratory, and were mainly 
descriptive. Response to treatment was analysed on the basis of intention to 
treat for all subjects who completed the study. The Shapiro-Wilk test was used 
to assess normality of data. Data were presented as mean and standard 
deviation (SD) or median and inter-quartile range (IQR) for non-parametric 
data. Difference in baseline characteristics between the treatment groups was 
analysed using independent t-test or Mann Whitney U test for non-parametric 
data. Analysis of co-variance (ANCOVA) was used to compare the outcomes at 
the end of the study between the two treatment groups with the baseline 
measures entered as covariates. Descriptive statistics for ANCOVA were 
presented as mean and SD. Wilcoxon Signed Rank test was used to determine 
whether there was difference in fibrosis risk scores before and after treatment.  
 
Spearman’s correlation was used to determine any association between 
markers of insulin resistance, endothelial function, oxidative stress, vascular 
inflammation and liver transaminases at baseline. Multivariate analysis was 
used to determine if associations remain significant after adjustment for 
confounding factors.  
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Baseline characteristics and ANCOVA were analysed for participants who 
completed the study only, whereas Spearman’s correlation was analysed for all 
participants including those who did not complete the study. 
 
All analyses will be performed using Statistical software IBM SPSS Statistics 22.0 
for windows (IBM Corporation 2013). All tests will be performed at a 5% level of 
significance. 
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Results 
Participant recruitment 
Medical notes and letters of 80 patients with NAFLD were reviewed and 11 
were not suitable for eligibility assessment. Three patients had acute medical 
issues (1 investigated for cardiac disease and 1 for malignancy, the other had 
acute gout flare-up), and were not screened. Out of the 66 patients assessed for 
eligibility to participate in this study, 17 patients were excluded as they did not 
satisfy the study criteria – 12 had low cardiovascular risk (QRISK2 <20%), 1 had 
probable haemochromatosis, 1 had antibiotics within 4 weeks, 1 had multiple 
courses of antibiotics, 1 exceeded alcohol consumption criteria and 1 had poor 
glycaemic control (HbA1c > 86 mmolmol). Five patients had other ongoing 
personal or medical issues so they did not wish to participate in the study. One 
patient was withdrawn as investigators were concerned that gut absorption 
may be affected by previous bowel surgery (right hemicolectomy and terminal 
ileum resection) and another withdrawn as it was not possible to draw venous 
blood samples despite multiple attempts. 
 
Of the 42 patients who participated, 35 completed the study. One patient was 
withdrawn as he was due to undergo bariatric surgery whilst 6 patients 
withdrew from the study for various reasons (taste of product, personal 
reasons, recurrent infections, nausea or diarrhoea). Figure 3.1 summaries 
participant recruitment.  
 
Recruitment began in May 2012 and ended in March 2014 when the study 
closed. Follow-up of the last participant was completed in January 2014. 
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Figure 3.1: Participant recruitment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline characteristics 
Thirty-five subjects were predominantly men with 28 males and 7 females. 
Their mean age was 57 ± 8 years (mean ± standard deviation) with a relatively 
short duration of NAFLD (median duration of NAFLD 0.3 ± IQR 2.0 years). 74% 
had T2DM or impaired fasting glucose. Majority were obese with a mean of BMI 
32.6 ± 5.0 kg/m2 and a mean waist circumference of 111.8 ± 12.6cm (mean for 
men was 110.9 ± 11.4cm and women was 115.3 ± 17.3cm). Baseline 
demographic characteristics are shown in Table 3.1 including those who did not 
complete the study as their baseline measurements of insulin resistance, 
Assessed eligibility 
n = 66 
 
Withdrawn, unable to 
obtain blood sample (n=1) 
 
Excluded (n=17), not meeting criteria 
Declined to participate (n=5) 
Withdrawn due to previous history of 
small bowel resection (n=1) 
 
 
 
 
Randomised 
n = 42 
 
Recruited 
n = 43 
 
Discontinued intervention (n=7) 
  - Due bariatric surgery (n=1) 
  - Other reasons (taste of products,   
    personal reasons, recurrent  
    infections, nausea or diarrhoea)  
    (n=6) 
 
 
Completed 
n = 35 
 
Case notes/letters 
reviewed  
n = 80 
 Pre-screening failure (n=11) 
Ongoing acute medical issues, not 
screened (n=3) 
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endothelial function, oxidative stress, vascular inflammation and liver 
transaminases were included in Spearman’s correlation analysis (in 
‘Outcomes’). 
 
Baseline metabolic parameters included a mean baseline blood pressure of 
134/82 ± 13/7 mmHg, total cholesterol 4.42 ± 1.15mmol/l, HDL 1.06 ± 
0.29mmol/l, LDL 2.43 ± 1.06 mmol/l, triglycerides 2.00 ± 0.88 mmol/l and 
HbA1c 53 ± 14 mmol/mol. Table 3.2 shows baseline metabolic parameters of 
subjects who completed the study. Baseline characteristics of majority of the 
subjects fit the definition of the metabolic syndrome presented in Table 1.1. 
 
About half the subjects were taking cardiovascular prevention medications 
(Figure 3.2) – 17/35 (49%) on an ACE inhibitor or angiotensin receptor blocker; 
16/35 (46%) on other antihypertensive agents and 17/35 (49%) on a statin. Only 
a small proportion was taking aspirin (6/35; 17%). 60% (21/35) of subjects were 
taking glucose lowering medications (Figure 3.3) and all of them took 
metformin either alone or in combination with other glucose lowering agents 
(Figure 3.4). 
 
Comparison of baseline characteristics of the VSL#3- treated group and the 
placebo-treated group showed no significant difference in these parameters 
(Table 3.3). Exclusion of an outlier in the diastolic BP (DBP) and total cholesterol 
data did not change the analysis results. Baseline HOMA-IR was lower in the 
VSL#3-treated group with this difference just reaching statistical significance 
(1.6 ± IQR 1.7 v placebo 3.0 ± IQR 1.8; p=0.04). This difference remained even 
with the exclusion of subjects on insulin therapy. 
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Table 3.1: Baseline demographic characteristics 
Trial 
No 
Age 
(yrs)  
Sex 
 
Duration of 
NAFLD (yrs) 
Weight 
(kg) 
Height 
(m) 
BMI 
(kg/m2) 
Waist circ 
(cm) 
CV risk 
(%) 
002 70 F 2 93.3 1.66 33.9 123.1 75* 
003 65 F 1 121.9 1.74 40.3 117.3 80 
006 55 M 5 104.1 1.806 31.9 108 33 
008 56 M 7 74.7 1.71 25.5 93.2 20 
010 57 M 0 103.7 1.61 40 110.6 63 
011 56 M 0 90.9 1.78 28.6 102 30 
012 45 M 0.3 83 1.73 27.7 92.7 24 
014 64 M 0.3 90.9 1.74 30.2 104.6 51 
016 63 F 12 106.8 1.68 37.8 120.2 45 
017 52 M 2 117.7 1.81 35.9 115.3 47 
018 54 M 6 88.2 1.75 28.8 90.4 43 
020 65 M 1 101.5 1.65 37.3 128.3 81 
021 52 M 1 127.1 1.81 34.4 124.4 65 
022 55 M 0 95.5 1.67 34.2 118.8 53 
023 57 M 0 110.3 1.83 32.9 115.6 20 
024 66 M 0 113.9 1.76 36.8 122.6 89 
025 55 M 0.25 120.2 1.73 40.2 127.7 43 
026 69 M 1 102.9 1.79 32.3 115.4 66 
027 42 F 0 142.6 1.68 50.5 145.6 22 
029 63 M 1 90.1 1.77 28.8 92 59* 
030 65 F 0.25 73.8 1.63 27.8 91.4 21 
031 46 M 0 95.7 1.76 30.9 108.5 22 
032 55 M 0.2 98.3 1.77 31.4 115.5 26 
033 60 F 1 90.2 1.7 31.2 106.3 38 
034 53 M 3 82.5 1.73 27.6 95 21 
035 62 M 0.2 101 1.82 30.5 115 71 
036 65 M 5 109.6 1.79 34.2 122.7 56 
037 46 M 0.3 116.4 1.91 31.9 117.2 30 
039 68 M 2 88.4 1.69 31 116.5 70 
040 49 M 0 77.5 1.73 25.9 99.1 22 
041 57 M 1 105.7 1.8 32.6 114.5 29 
042 56 M 0 92.5 1.76 29.9 107.7 83 
043 65 M 0 103.5 1.81 31.6 126.5 76 
044 41 M 0.25 84 1.74 27.7 104.9 26 
045 61 F 0.2 76.9 1.59 30.4 103.4 24 
001^ 67 F 5 113.6 1.7 39.3 112.9 57 
004^ 56 M 14 160.7 1.77 45.4 140.8 45 
005^ 70 M 5 75.4 1.68 26.7 88.8 64* 
007^ 59 F 3 76.9 1.6 30 90.2 27 
015^ 49 M 5 108.4 1.91 29.7 101.4 27 
019^ 52 F 15 110.7 1.57 44.9 129 47 
028^ 64 F 2 90.4 1.62 34.3 116 39 
^ did not complete the study 
* original Qrisk2 score was used as multiplying by 1.87 would exceed 100% 
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Table 3.2: Baseline metabolic parameters 
Trial 
No 
SBP 
(mmHg) 
DBP 
(mmHg) 
T-chol 
(mmol/l) 
HDL 
(mmol/l) 
LDL 
(mmol/l)  
Trig 
(mmol/l) 
HbA1c 
(mmol/mol) 
002 116 78 4.11 0.77 2.36 2.15 79 
003 146 69 3.89 0.81 2.36 1.58 84 
006 121 79 4.73 1 2.44 2.83 33 
008 113 75 5.14 0.96 3.27 2.01 31 
010 115 72 3.95 1.31 1.45 2.62 54 
011 159 79 3.22 0.64 1.25 2.92 68 
012 114 77 5.14 0.87 3.36 2.01 77 
014 139 89 3.84 1.42 1.86 1.24 54 
016 144 64 3.07 0.87 1.22 2.15 67 
017 149 76 4.07 0.85 2.51 1.57 54 
018 120 75 3.82 0.91 2.57 0.74 50 
020 122 80 3.93 0.99 2.13 1.78 65 
021 151 97 3.56 0.59 na 5.44 58 
022 139 82 4.42 0.95 2.58 1.96 65 
023 129 87 4.73 0.94 3.13 1.45 36 
024 136 79 3.1 0.9 1.52 1.5 62 
025 138 81 3.17 0.89 1.44 1.85 37 
026 133 80 3.65 0.83 2.02 1.75 38 
027 129 87 6.46 1.72 3.92 1.8 50 
029 143 83 4.87 1.86 2.77 0.53 37 
030 123 79 4.53 1.22 2.39 2.03 48 
031 127 90 5.8 0.97 3.63 2.65 38 
032 132 85 4.36 1.37 2.31 1.5 41 
033 138 90 7.82 1.6 5.28 2.06 50 
034 131 81 4.64 1.28 2.58 1.72 40 
035 144 80 4.5 0.84 1.97 3.71 70 
036 129 81 2.97 0.98 1.24 1.65 58 
037 123 78 4.44 1.17 1.89 3.03 48 
039 151 92 3.09 0.81 1.62 1.45 63 
040 142 91 6.65 1.16 4.77 1.58 39 
041 139 91 5.49 1.31 3.41 1.7 38 
042 138 85 4.19 1 2.3 1.95 52 
043 163 98 4.99 1.19 3.07 1.6 52 
044 121 81 2.4 0.75 1.26 0.85 56 
045 128 80 5.91 1.39 3.47 2.32 46 
SBP – systolic blood pressure; DBP – diastolic blood pressure; t-chol – total 
cholesterol; HDL – high density lipoprotein; LDL – low density lipoprotein; trig – 
triglycerides; HbA1c – glycosylated haemoglobin 
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Figure 3.2: Subjects on cardiovascular prevention medications  
 
ACEI – ACE inhibitor; ARB – Angiotensin receptor blocker 
Anti-HTN – antihypertensive medications 
 
Figure 3.3: Subjects taking glucose lowering therapies 
 
0 – not on any glucose lowering agents; 1- 4 – one or a combination of glucose 
lowering therapies 
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Figure 3.4: Types of glucose lowering agents taken by subjects
 
 
Table 3.3: Comparison of baseline characteristics between treatment groups 
Measurements VSL#3 group 
(n=19) 
Placebo group 
(n=16) 
p value 
Age (y) 57 ± 8 58 ± 7 0.96 
Gender (male/female)§ 15/4 13/3 0.91 
Duration NAFLD (y)§ 0.25 ± IQR 2.0 1.0 ± IQR 1.5 0.27 
T2DM (or IFG)§ 15 (79%) 11 (69%) 0.61 
Smoker§ 2 (11%) 2 (13%) 0.94 
Alcohol (units/wk)§ 1 ± IQR 8 6 ± IQR 8 0.10 
BMI (kg/m2) § 31.2 ± IQR 9.1 31.9 ± IQR 4.0 0.57 
Waist circ (cm) 112.2 ± 14.3 111.2 ± 10.7 0.81 
SBP (mmHg) 133 ± 13 135 ± 12 0.56 
DBP (mmHg) 82 ± 8 82 ± 7 0.91 
Total chol (mmol/l) 4.51 ± 1.38 4.31 ± 0.85 0.61 
HDL (mmol/l)§ 0.98 ± IQR 0.35 0.95 ± IQR 0.54 0.66 
LDL (mmo/l) 2.58 ± 1.18 2.42 ± 0.70 0.64 
Trig (mmol/l)§ 1.80 ± IQR 0.45 1.80 ± IQR 1.27 0.73 
HbA1c (mmol/mol)§ 54 ± IQR 17 47 ± IQR 19 0.23 
ALT (iu/L)§ 43 ± IQR 56 51 ± IQR 30 0.96 
AST (iu/L) 40 ± 16 40 ± 15 0.99 
§Mann Whitney U test for non-parametric data; ^one missing value in LDL data 
as triglyceride (>4.5 mmol/l) was too high for LDL calculation. 
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Outcomes 
Six of 35 subjects (17%) had a positive LBHT suggesting the presence of small 
intestinal bacterial overgrowth. In the VSL#3-treated group, the presence of 
SIBO increased from 11% (2/19) to 16% (3/19). SIBO in the placebo-treated 
group was unchanged (25%; 4/16).  
 
Primary outcome measure 
There was no statistically significant difference between the effects of VSL#3 
and placebo treatment on markers of insulin resistance, endothelial function, 
oxidative stress, vascular inflammation and liver transaminases (ALT and AST).  
Exclusion of outliers and log transformation of these parameters did not change 
the analysis results significantly. In addition, there was no significant difference 
in insulin resistance between the two treatment groups after exclusion of 
subjects on insulin therapy. Lipid hydroperoxide levels were undetectable in all 
but one subject so it was excluded from data analysis. Comparison of 
measurements before and after both interventions is shown in Table 3.5.  
 
The mean difference in post intervention mode ASQ score between VSL#3 and 
placebo treatment just reached statistical significance suggesting that the 
placebo-treated group had lower post intervention mode ASQ score than the 
VSL#3-treated group (p=0.048) [Table 3.4].  
 
VSL#3 and placebo treatment did not change NAFLD fibrosis risk score and 
FIB4-index score significantly (Figure 3.5 and 3.6 illustrate NAFLD fibrosis risk 
score and FIB-4 index for VSL#3 group, Figure 3.7 and 3.8 for placebo group).  
 
Four cGMP values were not measurable (patient ID 021, 032 and 037 from 
placebo group, and 044 from VSL#3 group). HOMA-IR data had two sets of 
missing values as insulin levels were outside the HOMA calculator range 
(subject ID 029 from placebo group and 036 from VSL#3 group). HbA1c in the 
placebo group had one missing value (subject ID 017). LDL cholesterol had 
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missing data for subject ID 021 from placebo group and 035 from VSL#3 group 
as triglycerides were > 4.5mmol/l which preclude LDL cholesterol calculation. 
SBP and DBP values were missing after intervention in the placebo group 
(patient ID 026). These data were excluded from respective analyses. 
 
There was no statistically significant difference in outcomes of metabolic 
parameters following treatment with either VSL#3 or placebo. Table 3.6 
illustrates these parameters before and after both interventions. 
 
 
 
Table 3.4: Unadjusted and Adjusted Intervention Means and Variability for 
Post Intervention Mode ASQ score with Pre Intervention Mode ASQ score as a 
Covariate 
  Unadjusted Adjusted 
 N Mean SD Mean SE 
Placebo 11 95 13 91 2 
VSL#3 10 95 16 99 3 
N = number of participants, SD = standard deviation, SE = standard error 
Covariate: pre-intervention mode ASQ score = 95 
Mode ASQ score measured in C2m 
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Table 3.5: Effects of VSL#3 and placebo on markers of insulin resistance, 
endothelial function, oxidative stress, vascular inflammation and liver injury 
 Before 
VSL#3 
After 
VSL#3 
Before 
placebo 
After 
placebo 
HOMA-IR 2.2 ± 1.9 2.2 ± 1.5 3.1 ± 1.8 3.0 ± 1.4 
PPG-GTN 28 ± 6 25 ± 8 24 ± 7 23 ± 6 
PPG-Salb 9 ± 8 8 ± 4 9 ± 6 9 ± 6 
VCAM-1 (ng/ml) 536 ± 305 524 ± 262 705 ± 423 722 ± 423 
cGMP (pmol/l) 178 ± 57 159 ± 43 187 ± 40 183 ± 57 
ACR (mg/mol) 2.6 ± 9.4 3.6 ± 14.2 3.0 ± 7.3 2.5 ± 5.5 
GSH:GSSG 22 ± 10 26 ± 13 20 ± 12 21 ± 9 
CuPRAC (mM Asc 
[AEAC]) 
0.46 ± 0.04 0.47 ± 0.07 0.43 ± 0.06 0.44 ± 0.07 
hsCRP (mg/l) 3.0 ± 2.5 3.9 ± 6.1 3.2 ± 5.3 2.7 ± 2.7 
ALT (iu/l) 56 ± 31 51 ± 32 51 ± 19 49 ± 26 
AST (iu/l) 40 ± 16 38 ± 20 40 ± 15 41 ± 17 
Mode ASQ (C2m) 91 ± 14 95 ± 16 99 ± 10 95 ± 13 
Missing data: HOMA-IR patient ID 029 [A] and 036 [B]; cGMP patient ID 021, 
032, 037 [A] and 044 [B].  
Subset analysis of ASQ: no data for patient ID 021, 025, 032 and 045 [A]; 016, 
020, 027, 033, 036, 039 and 044 [B]. Missing ASQ data: patient ID 002 [A], 010 
and 040 [B].  
[A] = placebo and [B] = VSL#3 
 
 
Table 3.6: Effects of VSL#3 and placebo on metabolic parameters 
 Before 
VSL#3 
After 
VSL#3 
Before 
placebo 
After 
placebo 
SBP (mmHg) 133 ± 13 130 ± 11 135 ± 13 128 ± 17 
DBP (mmHg) 82 ± 8 80 ± 7 82 ± 17 78 ± 11 
Total chol (mmol/l) 4.51 ± 1.38 4.42 ± 1.27 4.31 ± 0.85 4.50 ± 1.06 
HDL (mmol/l) 1.07 ± 0.26 1.09 ± 0.24 1.05 ± 0.34 1.06 ± 0.35 
LDL (mmol/l) 2.58 ± 1.18 2.56 ± 1.02 2.42 ± 0.70 2.50 ± 0.96 
Trig (mmol/l) 1.89 ± 0.57 1.91 ± 1.00 2.11 ± 1.15 2.39 ± 1.42 
HbA1c (mmol/mol) 54 ± 12 55 ± 12 50 ± 16 51 ± 15 
Fructosamine 
(mol/l) 
257 ± 44 263 ± 49 257 ±53 266 ± 64 
Missing data: SBP and DBP patient ID 026 [A]; LDL patient ID 021 [A] and 035 
[B]; HbA1c patient ID 017 [A]. 
[A] = placebo and [B] = VSL#3 
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Figure 3.5: NAFLD fibrosis risk score before and after VSL#3 (n=19) 
 
preRx – before treatment; postRx – after treatment 
 
 
Figure 3.6: FIB4-index before and after VSL#3 (n=19) 
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Figure 3.7: NAFLD fibrosis risk scores before and after placebo (n=16) 
 
preRx – before treatment; postRx – after treatment 
 
 
Figure 3.8: FIB4-index before and after placebo (n=16) 
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Secondary outcome measure 
There was moderate correlation between VCAM-1 and hsCRP (rho=0.392, 
p=0.01); moderate correlation between hsCRP and GSH:GSSG (rho=0.325, 
p=0.04); and moderate correlation between HOMA-IR and AST (rho=0.489, 
p<0.01) at baseline. These relationships are illustrated in Figure 3.9, 3.10 and 
3.11 respectively.  
 
A summary of correlation analysis results is presented in Table 3.7. Urinary ACR 
was not analysed as a number of ACR values were undetectable and despite 
categorising them into clinically meaningful groups, the sample size in these 
groups were too uneven to run correlation analysis on the urinary ACR data. 
There were 3 missing values for cGMP (subject ID 015, 037 and 044) and 
HOMA-IR (subject ID 004, 029 and 036) respectively, and these were excluded 
from Spearman’s correlation analysis.  
 
Figure 3.9: Association between baseline hsCRP and sVCAM-1 
 
  - - - - - 95% confidence interval 
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Figure 3.10: Association between baseline hsCRP and GSH:GSSG ratio
 
- - - - - 95% confidence interval 
 
Figure 3.11: Association between baseline HOMA-IR and AST 
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Table 3.7: Correlation analyses of baseline markers of insulin resistance, 
endothelial function, oxidative stress, vascular inflammation and liver 
transaminases 
 
     rho – Spearman’s correlation analysis 
 
 
 
Measurements rho p value 
VCAM + cGMP -0.149 0.35 
VCAM + PPG-Salb -0.086 0.59 
VCAM + GSH:GSSG 0.052 0.74 
VCAM + TAOS -0.176 0.26 
VCAM + hsCRP 0.392 0.01* 
VCAM + HOMA-IR 0.283 0.80 
VCAM + ALT -0.131 0.41 
VCAM + AST 0.275 0.08 
HOMA-IR + cGMP -0.002 0.99 
HOMA-IR + PPG-Salb -0.062 0.71 
HOMA-IR + GSH:GSSG -0.202 0.22 
HOMA-IR + TAOS -0.099 0.55 
HOMA-IR + hsCRP 0.148 0.37 
HOMA-IR + ALT 0.234 0.15 
HOMA-IR + AST 0.489 0.001* 
cGMP + hsCRP -0.116 0.48 
cGMP + PPG-Salb 0.316 0.05 
cGMP + GSH:GSSG -0.073 0.67 
cGMP + TAOS 0.243 0.14 
cGMP + ALT 0.000 1.00 
cGMP + AST -0.094 0.57 
PPG-Salb + hsCRP -0.172 0.28 
PPG-Salb + GSH:GSSG -0.038 0.81 
PPG-Salb + TAOS 0.140 0.38 
PPG-Salb + ALT 0.074 0.64 
PPG-Salb +AST -0.033 0.83 
hsCRP + GSH:GSSG 0.325 0.036* 
hsCRP + TAOS -0.058 0.72 
hsCRP +ALT -0.207 0.19 
hsCRP + AST 0.148 0.35 
GSH:GSSG + TAOS 0.042 0.79 
GSH:GSSG + ALT 0.012 0.94 
GSH:GSSG + AST -0.005 0.97 
TAOS + ALT -0.089 0.58 
TAOS + AST -0.185 0.24 
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Medication changes and adherence 
Four subjects had medication alterations, as advised by their medical 
physicians, during the intervention period. In the VSL#3-treated group, one 
had statin dose reduction (simvastatin from 80mg to 40mg) and one had an 
antihypertensive medication changed (amlodipine to bendroflumethiazide). In 
the placebo-treated group, one stopped statin therapy and one was started on 
statin 8 days before the end of their intervention period. Glucose lowering 
therapies did not change throughout the study period for all subjects. One 
subject from the VSL#3-treated group was deemed non-compliant, taking 63% 
of study products only. These subjects were included in the results analyses on 
the basis of intention to treat.  
 
Harms 
Of those subjects who reported an adverse event, 6 subjects (ID 005, 007, 015, 
019, 020 and 023) were treated with VSL#3 and 4 subjects (ID 003, 028, 031 
and 032) with placebo. No serious adverse event was reported, however, there 
were 15 adverse events (Table 3.8) which were assessed in a trials steering 
committee. None of these was deemed to be directly related to the study 
product. Nonetheless, three subjects (ID 007, 015 and 023) who were treated 
with VSL#3 probably had bloating related to VSL#3.  
 
In the VSL#3-treated group, a total of 10 adverse events were reported, of 
which 4 were urinary tract infections (UTIs). The frequency of UTIs observed 
may be related to subjects having a higher risk of developing UTI in view of a 
background of T2DM and previous history of recurrent UTIs.  
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Table 3.8: Reported adverse events 
AE no. Patient trial no. Symptom(s) Serious (Y/N) Relatedness Expectedness 
1 007 Excessive bloating* 
Sore lips^ and genital thrush^ 
N *Possibly 
^Unlikely 
*Expected 
^Unexpected 
2 003 Toe infection (traumatic) N Unrelated Unexpected 
3 005 Urinary tract infection N Unrelated  Unexpected 
4 007 Urinary tract infection N Unrelated Unexpected 
5 007 Urinary tract infection N Unrelated Unexpected 
6 019 Persistent nausea N Unrelated Unexpected 
7 015 Bloating N Probably Expected 
8 028 Diarrhoea N Unlikely Unexpected 
9 023 Intermittent bloating N Probably Expected 
10 015 Urinary tract infection N Unrelated Unexpected 
11 020 Nausea N Unlikely Unexpected 
12 032 Back pain radiating to leg N Unrelated Unexpected 
13 032 Toe infection (after removal of toe nail) N Unrelated Unexpected 
14 015 Perianal rash N Unrelated Unexpected 
15 031 Abdominal cramps N Possibly Unexpected 
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Discussion 
Probiotics have anti-inflammatory and antioxidant properties with beneficial 
effects on metabolic parameters. In this study, VSL#3 probiotic 
supplementation was used to assess the impact of probiotics on markers of 
insulin resistance, endothelial function, oxidative stress, vascular inflammation 
and liver injury in patients with NAFLD. The main findings are summarised 
below: 
1. VSL#3 did not improve insulin resistance, endothelial dysfunction, oxidative 
stress, inflammation or liver injury. 
2. There was a significant association between inflammation and endothelial 
dysfunction, and between inflammation and oxidative stress at baseline. 
3. Insulin resistance was significantly associated with AST, a surrogate marker of 
liver injury, at baseline. 
4. Mode ASQ score was significantly reduced after placebo treatment compared 
with VSL#3 treatment.  
For point 2, when Bonferroni correction was applied, associations would be 
considered statistically significant when p value is < 0.0014. In other words, only 
the correlation between HOMA-IR and AST (p=0.0010) remain statistically 
significant. Bearing in mind that Bonferroni correction may increase the 
possibility of Type II errors such that genuinely significant results are dismissed 
(158), I have written up the correlation results as they are without Bonferroni 
adjustment. Nevertheless, it is prudent to interpret the association between 
inflammation and oxidative stress with caution, given a p value of 0.036, even 
though it seems reasonable to assume that these processes occur in tandem. 
 
In the following sections, I will compare and discuss the findings of the study 
with other relevant published studies, and explore the limitations of the study 
which may have contributed to the results observed.  
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Comparison with relevant findings from published studies 
There are only a handful of published studies evaluating the effects of VSL#3 
on patients with liver disease to date. Most VSL#3-related studies on liver 
disease are based on experimental animal models previously discussed in 
‘Background’. Of human studies published, liver diseases from various causes 
(such as viral hepatitis) have been included and the majority of them assessed 
the benefits of VSL#3 on hepatic encephalopathy and portal hypertension. Of 
note, there are currently no published studies exploring the effects of VSL#3 
on endothelial function in patients with NAFLD.  
Alisi et al. [2014] conducted a double-blind, randomised controlled trial on 40 
obese children with biopsy-proven NAFLD using 1 sachet VSL#3 (concentration 
of bacteria not stated) per day for children aged < 10 years and 2 sachets per 
day for children > 10 years over 4 months. Compared with the placebo group, 
those on VSL#3 were less likely to develop moderate-severe fatty changes 
defined by liver ultrasound and had significant reduction in BMI. There was no 
difference in insulin resistance, triglyceride and ALT levels between VSL#3 and 
placebo treatment (101).  
 
Compared with my study, subjects in the Alisi [2014] study were treated for a 
longer duration and prescribed a low calorie diet with a recommended exercise 
programme. As lifestyle interventions were the same between treatment 
groups, it would seem that VSL#3 supplementation leads to weight loss 
beyond lifestyle adjustments. There was no significant difference in BMI in my 
study following either VSL#3 or placebo intervention (median BMI pre v post 
intervention: 31.2kg/m2 v 31.8kg/m2; 31.9kg/m2 v 32.1kg/m2 respectively). 
Perhaps a longer duration of treatment in my study may have shown possible 
beneficial effects of VSL#3 on the parameters measured.  
 
Similarly, another study reported positive findings of VSL#3 when given for a 
slightly longer duration. Loguercio et al. [2005] assessed the effects of VSL#3 
on oxidative stress in patients with various chronic liver diseases (22 patients 
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with NAFLD, 20 with alcoholic fatty liver disease and 36 with hepatitis C). All 
patients received 2 sachets of VSL#3 twice daily (450 billion bacteria per 
sachet) for 3 months. There was a significant reduction in plasma markers of 
lipid peroxidation (malondialdehyde and 4-hydroxynonenal) and oxidative 
stress (S-nitrosothiols) in patients with NAFLD (98).  
 
Rajkumar et al. [2014] assessed the effects of VSL#3 and omega-3 fatty acid on 
60 overweight, otherwise healthy, Indian adults in a randomised controlled trial 
(95). VSL#3 was administered at a dose of 112.5 billion bacteria (one capsule) 
per day over 6 weeks. There was improvement in insulin sensitivity and lipid 
profile, and reduction in hsCRP and proinflammatory cytokines (TNFα, IL-1β and 
IL-1) following VSL#3 treatment. Given the ethnicity of patients in that study, 
majority would be considered obese with a mean BMI of 28.8kg/m2 (range 27-
30). As there is a strong association between obesity and NAFLD, these results 
may be applicable to the NAFLD population even though they could not be 
replicated in the present study.  
 
Conversely, a recently published study reported no significant change in hsCRP 
and inflammatory markers (TNFα, IL-6 and IL-10) in healthy adults aged 65-85 
years after an 8 week intervention with a personalised diet and VSL#3 (224 
billion bacteria per day) compared with diet alone (159). However, there was an 
improvement in erythrocyte sedimentation rate in both treatment groups 
although it was only significant in the diet alone group. 
 
There are no reported studies investigating ASQ data in response to VSL#3 in 
patients with NAFLD and this is the first study to do so. However, it should be 
noted that ASQ has not been fully validated in patients with NAFLD and the 
threshold that defines the severity of fatty infiltration has not been determined. 
Toyoda et al. [2009] reported good correlation between ASQ data and grades of 
liver fibrosis in 148 patients with histologically proven chronic hepatitis C. The 
severity of liver fibrosis according to the median values of mode ASQ (expressed 
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as C2m) was classified as 124.5 (range 109.5-148.0) for patients without fibrosis 
or mild fibrosis, 131.5 (116.0-146.0) for patients with moderate fibrosis, and 
144.0 (117.5-154.0) for patients with severe fibrosis (157).   
 
The median values of mode ASQ (C2m) of subjects in the present study suggest 
that the majority of them did not have significant fibrosis [placebo group: 
median value of mode C2m was 101.0 (range 77.0-114.0) before treatment and 
93.0 (83.0-123.0) after treatment; VSL#3 group: 89.0 (73.0-110.0) before 
treatment and 96.0 (72.0-115.0) after treatment]. However, no further 
interpretation can be made of the data due to lack of validated studies.  
 
Limitations of the study 
Several factors may have contributed to the results of this study. Here, the 
limitations are explored broadly in 3 categories: patient cohort, methodology 
and chosen parameters.  
 
Patient Cohort 
The 10-year CV risk may have been overestimated by multiplying the QRISK2 
score with a factor of 1.87 based on epidemiological data of CV events in 
patients with NAFLD (81). Conversely, all these patients may be at high risk of 
CVD but the majority of them have reasonably well-controlled cardiometabolic 
parameters such as blood pressure, lipid profile and glycaemic control. 
Approximately 50% of patients were taking statin therapy and an ACE inhibitor 
(or ARB) and 60% taking metformin. These medications have been shown to 
reduce endothelial dysfunction, vascular inflammation and oxidative stress 
(160–162). It is possible that processes underlying atherosclerosis have been 
attenuated by these medications, thus reducing the potential beneficial effects 
that would, otherwise, be seen with VSL#3 supplementation.  
 
The average duration of NAFLD was relatively short with 54% of subjects 
diagnosed less than a year before participating in the study. One may speculate 
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that these subjects have less severe liver disease and epidemiological studies 
have shown that steatosis alone is relatively benign (9,11,12).  
 
Methodology 
Sample size 
The number of subjects in the study was small so significant changes with 
VSL#3 may be less easily detected. It is worth noting that a sample size 
calculation could not be made at the outset of the study because it was not 
possible to identify a primary outcome measure from the existing literature to 
make such a calculation As a result, this study is treated as an exploratory, 
proof-of-concept study. 
 
Matched controls 
It was assumed that patients with NAFLD, in this study, are at high 
cardiovascular risk with raised markers of oxidative stress, inflammation, 
endothelial dysfunction and insulin resistance. The absence of age and sex-
matched controls to confirm this assumption is seen as a limitation of the study 
design. However, other studies comparing patients with and without NAFLD 
(i.e. controls) have shown that those with NAFLD were more insulin resistant 
(62) with higher circulating pro-inflammatory markers (71) and had evidence of 
endothelial dysfunction (66). 
 
Dose and duration of VSL#3 
There is limited published literature on VSL#3 in patients with NAFLD 
particularly in evaluating its effects on cardiovascular risk. The majority of these 
studies assessed liver-related endpoints in cirrhotic patients. The dose and 
duration of VSL#3 used in human studies vary considerably (112.5 billion 
bacteria to 3,600 billion bacteria per day; 6 weeks to 6 months) (95,98,102,163). 
So far, no ideal dose and duration have been recommended. Notably, 
favourable alteration of gut flora associated with improvement in insulin 
sensitivity and metabolic parameters were documented with 1 capsule of 
VSL#3 (112.5 billion bacteria) per day over 6 weeks (95). There was reduction 
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in markers of oxidative stress with 3 months of 1,800 billion bacteria daily (98). 
In the absence of a consensus on VSL#3 dose and duration, 1,800 billion 
bacteria per day administered over 10 weeks seemed reasonable. 
 
Compliance 
Subjects were asked to return all study products, used and unused sachets, to 
the study team at their last visit. These were counted and verified by the 
research team before disposal by the Pharmacy Department, QAH. All subjects 
were telephoned about a week after starting the study products to ensure they 
are taking the correct dose, keeping used products and storing unused products 
appropriately. An instruction sheet was also given to each participant. There 
was no biochemical test to assess compliance to study products and it relied 
upon subjects returning study products, self-reporting of missed doses and 
sachet counts. 
 
Liver biopsy 
The majority of the subjects did not have pre-existing liver biopsy so the 
severity of their liver disease was largely unknown. One may speculate that 
subjects in the study had less severe liver disease so no discernible benefits 
were seen with VSL#3. A liver biopsy before and after intervention would 
identify histopathological changes within the liver following VSL#3 which may 
not be detected on fibrosis risk scores, liver enzymes and liver imaging. On the 
other hand, having a liver biopsy as part of the study protocol may be a 
deterrent to participation for some patients.  
 
In clinical practice, not all patients diagnosed with NAFLD require a liver biopsy 
at the outset as management of simple steatosis differs from that of NASH, 
fibrosis and cirrhosis. Fibrosis risk scores are used as a tool to predict the 
likelihood of advanced fibrosis and rationalise the need for a liver biopsy. 
Patients with more severe liver disease require long term liver surveillance in 
Secondary Care, whereas those with simple steatosis require lifestyle 
adjustment and addressing cardiovascular risk factors which are usually 
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undertaken by their GPs. Liver biopsy is invasive with potentially serious, life-
threatening complications; is expensive; and not without sampling error. The 
risks of a liver biopsy outweigh the benefits in most patients with simple 
steatosis. Hence the inclusion of patients with and without liver biopsy allows 
the results of the study to better reflect ‘real-world’ practice.  
 
Composition of gut flora and endotoxins levels 
The study did not include a test to establish whether VSL#3 changed gut 
microbiota or endotoxin levels, which are both implicated in the pathogenesis 
of NAFLD.  These measurements may have provided supporting mechanistic 
evidence that VSL#3 modifies gut microbiota and reduces gut-derived 
endotoxaemia in patients with NAFLD; and to a certain extent, changes in 
composition of gut microbiota in response to VSL#3 would indirectly indicate 
that subjects were compliant with treatment. 
 
Chosen parameters 
Insulin resistance 
The hyperinsulinaemic euglycaemic glucose clamp technique, developed by De 
Fronzo et al. [1979], is generally considered the reference standard for 
quantitative assessment of insulin sensitivity/resistance in humans (112). It 
involves infusion of insulin at a constant rate to achieve a higher basal insulin 
state (hyperinsulinaemic) and simultaneous infusion of 20% dextrose at a 
variable rate to maintain plasma glucose levels in the normal range 
(euglycaemic). It is assumed a steady-state of plasma insulin, blood glucose and 
glucose infusion rate (GIR) is achieved following constant insulin infusion and 
that there is complete suppression of hepatic glucose production by insulin. 
Under steady-state clamp conditions, the GIR is equivalent to the glucose 
disposal rate (or metabolised glucose, M) which is an index of tissue sensitivity 
to exogenous insulin. ‘M’ is inversely proportional to the degree of insulin 
resistance. This method is laborious, time consuming and expensive, therefore 
would not be feasible for this study.  
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HOMA described by Matthews et al. [1985] is a surrogate marker of insulin 
resistance calculated from fasting plasma insulin and glucose samples. It 
correlates well with hyperinsulinaemic euglycaemic clamp studies in normal 
subjects and those with diabetes (115). Bonora et al. (2000) demonstrated a 
strong correlation between these two methods irrespective of age, gender, 
obesity, diabetes and hypertension (164). In this study, three samples of paired 
fasting venous insulin and glucose were obtained 5 minutes apart to reduce 
intra-subject variability seen in single samples (114). This tool is not reliable in 
patients with severely impaired β-cell function and not validated for use in 
patients on insulin therapy. Even though the use of HOMA-IR in patients on 
insulin therapy has been previously reported (117–119), it has to be considered 
as a weakness of this study that HOMA-IR was used as a surrogate measure of 
insulin resistance in about 15% of subjects who were on insulin therapy. 
 
In a Brazilian study, HOMA-IR cut-off was determined from 116 patients with 
NAFLD without diabetes. Those with NAFLD were significantly more insulin 
resistant than age and sex –matched controls (HOMA-IR: 3.9 ± 2.8 v 1.2 ± 0.6 
respectively) (116). Other studies have reported similar HOMA-IR values in 
NAFLD (66,71). HOMA-IR was even higher in patients with NAFLD and diabetes 
(4.1 ± 2.1) and with metabolic syndrome (5.7 ± 4.3) (62,74). Subjects in this 
study had less insulin resistance than reported (HOMA-IR: 2.6 ± 1.8; or 2.2 ± 1.3 
if those on insulin treatment were excluded). This may be related to co-existing 
metformin use which has been shown to reduce HOMA-IR by a third in patients 
with T2DM (165). A systematic review and meta-analysis of treatments in 
NAFLD have shown significant reductions in HOMA-IR with metformin (23). 
 
There was a positive correlation between HOMA-IR and AST at baseline 
suggesting a relationship between insulin resistance and liver injury. This 
supports the pathogenesis of NAFLD in which insulin resistance and liver 
inflammation are closely linked. The IRAS study has shown a similar relationship 
between insulin resistance and liver transaminases (AST and ALT), however in 
that study insulin sensitivity index instead of HOMA was used (166). 
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Endothelial function 
Assessment of endothelial function can be undertaken with several methods 
and there is currently no consensus as to which method is best. In this study, 
peripheral vasomotor changes were measured by digital 
photoplethysmography (a pulse contour analysis) in response to an 
endothelium-independent vasodilator (GTN) and an endothelium-dependent 
vasodilator (Salbutamol). Donald et al. (2006) made a direct comparison 
between flow-mediated dilation (FMD) and pulse wave analysis (PWA)/pulse 
contour analysis (PCA) in adults and children. Reproducibility of FMD was much 
better than PWA and PCA, and the investigators suggested that FMD is the non-
invasive technique of choice for assessing endothelial function (167). Whilst 
both PCA and FMD are non-invasive, FMD is more technically demanding and 
requires an experienced investigator to perform the test.  
 
Whilst endothelial function measured by pulse wave velocity (70) has been 
reported, digital photoplethysmography has not been undertaken in patients 
with NAFLD. The baseline reflection index after Salbutamol (a well-known 
endothelium-dependent vasodilator) in our subjects was higher than patients 
with T2DM (9.0 ± 6.9% vs. 5.9 ± 1.8%) but reduced compared with the age and 
sex-matched control group in that study (11.8 ± 1.8%) (130). About 75% of 
patients in the study have T2DM and this may have contributed to endothelial 
dysfunction detected. Insulin plays a role in maintaining vascular endothelial 
function via its effects on nitric oxide (NO) production. When insulin signalling is 
impaired, for example in T2DM, there is a reduction in endothelial NO synthesis 
contributing to endothelial dysfunction (168). The degree of endothelial 
dysfunction may have been masked by subjects taking medications such as 
statins and ACE inhibitors (160,161).  
 
Of note, the reproducibility of digital volume pulse as measured by digital 
photoplethysmograpy is dependent on a number of factors including the 
ambient temperature, the perfusion of subjects’ index finger, subjects’ position, 
and sudden movements (e.g. a sneeze or cough) when measurement were 
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undertaken. These factors would be considered limitations of the test even 
though every effort was made to maintain similar conditions in which all 
subjects undergo digital photoplethysmography. Restriction on caffeine intake 
was not literally specified although subjects were instructed to fast for 12 hours 
and not to exercise 30 minutes before their study visit (Appendix 1). Endothelial 
function can be affected by caffeine intake and strenuous exercise; and in 
retrospect, subjects should have abstained from caffeine intake and strenuous 
exercise for 24 hours before each study visit. This omission is, therefore, 
regarded as a weakness of the study protocol.  
 
The mean baseline cGMP in this cohort of patients was slightly higher than 
healthy volunteers (172pmol/ml and 152pmol/ml respectively), however the 
overall range between the two were similar (117-227pmol/ml and 75-
219pmol/ml). The cGMP values for apparently healthy volunteers were taken 
from the manufacturer’s guide. One would expect reduced cGMP levels in 
NAFLD given the mechanisms involved in its development and its association 
with increased cardiovascular risk.  
 
Paradoxically, raised cGMP has also been reported recently. Felipo et al. [2013] 
examined alterations in cGMP homeostasis in morbidly obese patients with 
NAFLD and whether these changes reversed with bariatric surgery. Plasma 
cGMP concentration was significantly elevated in patients with NASH, but not 
steatosis, when compared with control subjects. This was reversed 18 months 
after bariatric surgery and weight loss. Interestingly plasma cGMP did not 
correlate with NO metabolites but with atrial natriuretic peptides (ANP). Under 
physiological conditions, the production of cGMP is modulated by two 
mechanisms: 1) soluble guanylyl cyclase activated by NO and 2) particulate 
guanylyl cyclase activated by ANP. In NASH and morbid obesity, it is possible 
that cGMP synthesis is upregulated by increased ANP and the release of cGMP 
into plasma is enhanced by cGMP transporter activity resulting in elevated 
plasma cGMP concentrations (169). To date, no studies have examined the 
relationship between cGMP and endothelial function in patients with NAFLD.  
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The mean baseline sVCAM-1 in the study (714ng/ml, range 277-1151ng/ml) was 
higher than healthy volunteers (531ng/ml, range 341-897ng/ml) suggesting that 
these patients with NAFLD have underlying endothelial dysfunction. The values 
for apparently healthy volunteers were taken from the manufacturer’s guide. 
Other studies have reported lower levels of sVCAM-1. Lucero et al. [2011] 
compared sVCAM-1 levels between patients with metabolic syndrome and 
those with metabolic syndrome and hepatic steatosis (74). There was no 
significant difference between the two groups (510 ± 129ng/ml without NAFLD 
v 511 ± 144ng/ml with NAFLD). Another study evaluated adhesion molecules in 
patients with idiopathic portal hypertension from various causes of liver disease 
including NAFLD. In the NAFLD group, sVCAM-1 was similar to the control group 
(453 ± 148ng/ml and 415 ± 216ng/ml respectively) (170).  
 
Patients with NASH have a higher frequency of microalbuminuria independent 
of age, gender, body mass index, smoking status, insulin resistance (HOMA-IR), 
and components of the metabolic syndrome suggesting a population at greater 
risk of CVD  (171). Majority of subjects have low-undetectable urine ACR 
indicative of a cohort with good metabolic control which may be related to 
medications taken and a relatively short duration of NAFLD presumably with 
steatosis alone. 
 
Oxidative stress 
Narashimhan et al. [2010] demonstrated a significantly lower glutathione ratio 
in patients with NAFLD and T2DM compared with those with T2DM alone, those 
with NAFLD alone and controls (GSH:GSSG ratio 4.1 ± 2.0 vs. 6.1 ± 2.0 vs. 17.6 ± 
7.2 vs. 23.7 ± 5.0 respectively) (148). In a study evaluating plasma markers of 
oxidative stress in patients with NASH, reduced GSH and glutathione ratio were 
significantly lower compared with healthy volunteers (21.1 ± 18.3 M vs. 33.1 ± 
22.2 M; and 0.9 ± 0.7 vs. 1.5 ± 0.8 respectively) (147). These levels were much 
lower than those found in my study (reduced GSH 491.0 ± 114.5 M; GSH:GSSG 
ratio 20 ± 10). The reason for this is unclear but a previous study conducted in 
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patients with T2DM, using the same technique for glutathione measurements, 
showed that subjects had higher reduced GSH (464 ± 195 M), and glutathione 
ratio (63 ± IQR 73). The author speculated that low oxidative stress levels may 
be related to a group of patients with pre-existing good metabolic control, the 
majority of whom were taking cardiovascular preventative medications (172). 
The subjects in my study probably have fairly benign liver disease given its 
duration (i.e. steatosis alone) and were taking cardiovascular disease 
prevention medications so they may also have relatively good metabolic 
control. 
 
There are a number of methods to quantify total antioxidant capacity (TAC) and 
the advantages of using the CUPRAC-BCS method are that it is simple and 
inexpensive, measures hydrophilic and lipophilic antioxidants, and works at 
physiological pH therefore there is no risk of underestimating (under acidic 
conditions) or overestimating (under alkaline conditions) TAC (173). However, 
CUPRAC-BCS has not been reported in patients with NAFLD and no direct 
comparison with the literature can be made.  
 
Inflammation 
Highly-sensitive CRP is a well established independent predictor of 
cardiovascular risk in addition to conventional risk factors therefore it was 
chosen as a marker to assess inflammation (72). The JUPITER study supports 
this as evidence by a significant reduction in cardiovascular risk associated with 
decrease in hsCRP on rosuvastatin (174). In this study, baseline hsCRP levels 
were suggestive of a cohort at high cardiovascular risk (hsCRP > 3mg/l) 
according to guidelines from the American Heart Association and Centers of 
Disease Control and Prevention (mean hsCRP 4.0mg/l) (175). Similar levels were 
reported in another study (mean hsCRP 4.5mg/l) in which hsCRP was associated 
with a significantly higher relative risk of CVD in patients with NAFLD compared 
with controls (73).  
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A moderate positive correlation was detected between hsCRP and sVCAM-1 at 
baseline. A similar relationship has been noted in a study evaluating pro-
inflammatory and atherogenic markers in NAFLD (74). This supports an 
association between endothelial dysfunction and inflammation in patients with 
NAFLD. There was also a moderate positive correlation between hsCRP and 
GSH:GSSG ratio which was unexpected. Elevated hsCRP, an indicator of 
inflammation, ought to be associated with reduced GSH:GSSG ratio, a marker of 
oxidative stress. Perhaps, this is due to upregulation of antioxidant mechanisms 
to compensate for pathological states such as chronic inflammation and once 
these mechanisms are overwhelmed, GSH:GSSG ratio falls. This is supported by 
increased total glutathione levels in endothelial and smooth muscle cells 
following exposure to peroxynitrite-mediated oxidative stress which suggests 
upregulation of glutathione synthesis as an adaptive response in the presence 
of oxidative stress (176). 
 
Liver transaminases 
Both ALT and AST are surrogate markers of liver injury. At baseline the mean 
ALT (52 ± 26 iu/l) and AST (42 ± 18 iu/l) levels were above the normal reference 
range suggesting the presence of liver injury. The definition of normal for liver 
transaminases has been debated. Prati et al. [2002] evaluated serum ALT in 
blood donors and suggested new thresholds for normal ALT defined as <30 iul/l 
for males and <19 iu/l for females which improved sensitivity (39.7% to 61.1%) 
and a slight reduction in specificity (97.6% to 95.5%) in screening patients for 
HCV (177). Whilst these ALT cut-offs are more for diagnostic purposes, they 
support the presence of liver injury in this cohort (males 52 ± 23 iu/l; females 54 
± 35 iu/l).  
 
Lactulose hydrogen breath test  
The prevalence of SIBO was lower in this study (17%) compared with quoted 
figures of 50-60% in other studies (42,43). As mentioned previously, LHBT has 
its own limitations due to heterogeneity of test protocols and definitions of a 
positive test. The sensitivity (68%) and specificity (44%) of LHBT at detecting 
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SIBO is relatively poor which may explain the discrepancy of SIBO rates seen in 
this study (110). Conversely, the lack of SIBO in our cohort may indicate that 
these subjects with relatively short duration of NAFLD were ‘metabolically’ 
healthier and thus, the potential beneficial effects of probiotics were not 
elicited in this study.  
 
Although jejunal aspirates obtained from endoscopy is considered the gold 
standard test to identify SIBO, this method is invasive, not cost-effective and 
culture results are not always representative. Hence, it is a simpler test to 
perform hydrogen breath test as it does not require other technical expertise 
and is non-invasive.  
 
ASQ 
Whilst ASQ provided information on fibrosis in the subset of subjects scanned, 
it was not possible to quantify the severity of hepatic steatosis due to lack of 
studies validating its use in patients with NAFLD. Most subjects did not have 
pre-existing liver biopsy to correlate ASQ data. Analysing baseline ASQ data of 
all subjects scanned, the median value of mode C2m for the placebo group was 
99.5 (range 77.0-121.0) compared with 98.0 (73.0-124.0) for the VSL#3 group.  
Each subject, from the two groups, with the highest mode C2m had a liver 
biopsy pre-dating the study.  The one from the VSL#3 group (C2m 124) had 
steatohepatitis and severe fibrosis, and the one from the placebo group (C2m 
121) had steatohepatitis and a degree of fibrosis which was not graded on the 
histological report. Although only two patients had a liver biopsy, one 
speculates that ASQ thresholds for fibrosis described in patients with chronic 
hepatitis C can be applied in patients with NAFLD.  
 
A recently published abstract suggests using a statistical model on ASQ (focal 
disturbance ratio) to quantify liver fat in patients with NAFLD (178). 
Unfortunately it was not possible to obtain this measurement retrospectively as 
a different software version was required. Other imaging modalities to evaluate 
fatty infiltration in the liver include CT, MRI and MR spectroscopy. Of these, MRI 
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and MR spectroscopy had the best diagnostic accuracy in detecting hepatic 
steatosis and quantifying the degree of fatty infiltration (179). None of these 
modalities was used as CT poses additional radiation exposure, and there were 
logistical issues in organising MRI and MR spectroscopy locally. 
 
Implication of this work and future studies 
This study does not support the hypothesis that probiotics improve markers of 
cardiovascular risk and liver injury in patients with NAFLD. Despite this a meta-
analysis of probiotics in NAFLD illustrated significant reductions in HOMA-IR, 
TNFα, total cholesterol, ALT and AST (180).  
 
A larger sample size would be needed to adequately assess the effects of 
probiotics in patients with NAFLD. The present study demonstrated a positive 
association between endothelial dysfunction and inflammation, and between 
oxidative stress and inflammation. Studies to explore these relationships further 
may help identify a primary outcome measure allowing sample size calculation 
for future clinical trials. As human studies examining markers of cardiovascular 
risk in NAFLD are lacking, the inclusion of matching controls will provide 
important baseline comparison of cardiovascular parameters. 
 
It would be interesting to explore whether probiotic supplementation prevents 
the progression of liver disease in patients with liver steatosis alone as NASH 
and more advanced forms of liver disease are associated with increased 
morbidity and mortality. A proposed new cut-off for ALT (males <30 iu/l and 
females <19 iu/l) that is more sensitive at detecting liver disease can be used to 
screen patients for future studies (177).  
 
Another area of research is the validation of ASQ liver imaging in patients with 
NAFLD. Currently ASQ is only validated to quantify the severity of fibrosis in 
patients with HCV. This imaging modality has the potential to quantify liver fat 
and if proven to do so, it offers clinicians a more accessible means of 
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determining the severity of fatty infiltration in the liver instead of a liver biopsy 
or MR spectroscopy.  
 
A number of limitations recognised in this study could have affected the 
outcome. Modificaton of gut microbiota with probiotics remains a potential 
therapeutic option in NAFLD, perhaps as an adjunct to lifestyle adjustments and 
weight loss. As NAFLD is closely linked with obesity and T2DM, it is rapidly 
becoming a global problem with significant health and socio-economic 
implications. To that end, further research on preventative strategies to delay 
the development of NAFLD and on therapeutic options to treat the condition is 
urgently needed.  
 
Going forward with future research, I suggest a randomised crossover trial with 
a longer intervention period of 24 weeks using the same dose as in this study, 
and recruiting subjects who are insulin-naive with biopsy proven NAFLD. Having 
biopsy proven subjects allows for staging of the severity of liver disease which 
may have some impact on the outcome as NASH (or more severe liver disease) 
seems to confer a worse prognosis. Sample size calculation should be 
undertaken, with the help of a statistician, to provide adequate statistical 
power for data analysis. Measurement of lipopolysaccharide, an indicator of gut 
endotoxinaemia, and analysis of changes in gut microflora from faecal samples 
should be included in the study. With extension on the intervention period, 
changes in carotid intima medial thickness (CIMT) as a measure of subclinical 
atherosclerosis may offer a clinically more meaningful way of assessing 
cardiovascular risk. Flow-mediated dilatation may be considered as an 
alternative non-invasive technique for assessing endothelial function provided 
there is appropriate training of investigators to perform it. For measurements 
of endothelial function, the study protocol ought to have clear instructions on 
strenuous physical activity, caffeine intake and alcohol intake i.e. abstinence for 
at least 24 hours before study visit. I would include hsCRP, biomarkers of 
endothelial function and oxidative stress, and liver imaging in future trials. 
Ideally a histological analysis of the liver before and after treatment should be 
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undertaken but liver biopsies are invasive and not realistic in a clinical trial 
setting.  Therefore, the use of liver imaging and fibrosis risk scores remain 
useful tools to assess liver fat content and the presence of fibrosis. At present, 
Acoustic Structural Quantification is not a validated tool to measure either of 
these in subjects with NAFLD. Until data emerge on its validity in NAFLD, future 
trials should use well-described methods to measure liver fat content such as 
MR spectroscopy and a FibroScan to assess the presence of liver fibrosis. 
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Appendix 
Appendix 1: Instructions for study visit 
 
The day before your visit: 
You should AVOID food high in fibre and slowly digesting foods such as bran, 
coarse breads, nuts, beans and similar vegetables, and starches. (Rice is 
allowed)  
 
You need to FAST OVERNIGHT – no food and alcohol for 12 hours before 
your visit. You can drink only water.  
 
If you are on insulin treatment, take your last insulin dose 24 hours before your 
visit (that means only take your morning insulin). If you experience high blood 
sugars and feel unwell, please contact me (Dr Lina Chong) on 02392286260 
 
 
On the day of you visit:  
Do not take your morning tablets (you can bring them with you and take them at 
lunchtime).  
 
PLEASE DO NOT SMOKE OR EXERCISE 30 MINUTES BEFORE YOUR VISIT 
 
 
